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MEF2- BOUND GENES MAY INFLUENCE ETHANOL SEDATION IN DROSOPHILA MELANOGASTER
Katlyn Marie Myers
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Advisor: Mike Grotewiel, PhD
Associate Dean for Graduate Education
Associate Professor, Human & Molecular Genetics
Alcohol Use Disorder (AUD) is a global health issue that affects millions of people every
year. This disorder has serious negative mental and physical consequences. Currently,
treatment options for this disorder are largely limited to psychological therapy, with very few
medications available to treat it. Being able to identify the environmental and genetic
components that influence AUD can help improve diagnosis and treatment options. Previous
studies in humans have shown a link between initial sensitivity and risk for alcohol abuse. Our
laboratory uses Drosophila melanogaster as a model to study the genetic and environmental
components of alcohol-related behaviors. Previous lab members found that the transcription
factor Mef2, the Drosophila ortholog to the MEF2B gene in humans, has a significant role in
ethanol sedation in flies. We consequently predicted that genes regulated or bound by Mef2 in
flies may also have a significant impact on ethanol sedation. Initial analysis of several candidate
genes revealed that transposon insertions and neuronal RNA interference (RNAi) against
spinster (spin) altered ethanol sedation. These genetic analyses, in combination with published
data, support the hypothesis that spin influences ethanol sedation and does so by functioning
downstream of Mef2.
xiii

Chapter 1-introduction
A. Alcohol Abuse and Alcohol Use Disorder
1. Alcohol Use Disorder
In 2016, more than half of the world’s population (3.1 billion people) said that they
currently drink alcohol (Hammer et al., 2018). Since then, the number of people who consume
alcohol has only increased (Hammer et al., 2018). Consuming alcohol can often lead to alcohol
abuse and alcohol use disorder (AUD). Alcohol abuse is a pattern of drinking too much alcohol
too often and frequently interferes with a person’s daily life (Anon, 2020). AUD is more complex
and is defined as a problematic pattern of alcohol use that has many clinically significant
impairments or distress outlined in the Diagnostic and Statistical Manual of Mental disorders
(DSM) (Kranzler and Soyka, 2018). An estimated 15 million people in the United States 18 years
old and older had some form of AUD in 2018. This included 9.2 million males and 5.3 million
females ("Alochol Use Disorder", NIH). Adolescents can be diagnosed with AUD as well, with
401,000 teenagers from 12-17 years of age receiving a diagnosis of AUD in 2018 ("Alochol Use
Disorder", NIH). There are over 88,000 alcohol-related deaths in the United States annually
(Kranzler and Soyka, 2018). Total alcohol consumption per capita in people 15 years and older is
projected to increase all over the world, making alcohol abuse very common and dangerous if
not treated properly (Hammer et al., 2018).
2. Characteristics of AUD
Unhealthy alcohol use includes any alcohol consumption use that puts a person’s health or
safety at risk or causes alcohol-related problems ("Alochol Use Disorder-diagnosis and
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treatment", Mayo Clinic). However, to be clinically diagnosed with AUD, individuals must meet
several criteria from the DSM. The severity of the disorder is based on the number of the
criteria met ("Alochol Use Disorder," NIH). Some of the criteria of AUD include inability to limit
the amount of alcohol an individual consumes, presence of alcohol cravings, development of
tolerance to alcohol, presence of withdrawal symptoms, and alcohol consumption interfering
with one’s daily lifestyle (“Alcohol Use Disorder-diagnosis and treatment,” Mayo Clinic). There
are several treatment options for AUD, such as psychiatric treatment (Alcoholics Anonymous,
individual psychotherapy) or prescription drugs. However, AUD is a complex disease with many
factors that can make it difficult to effectively treat. Consequently, treatment is frequently
unsuccessful (Ilgen et al., 2006).
3. AUD is a complex disease
AUD is a multi-factorial disease, meaning there is both a genetic and environmental
component to the disease (Reilly et al., 2017). The risk for developing AUD is therefore based
on an individual’s unique genetic composition and lifetime experiences (Litten et al., 2015). A
twin and adoption study showed that 50-60% of phenotypic variations in AUD are due to a
genetic component. There is also a 50% variance in the risk for AUD, and the age at the time of
diagnosis can be attributed to genetic factors (Matsushita and Higuchi, 2014). Another study on
the transition from alcohol abuse to dependence revealed that 26.6% of those with alcohol
abuse eventually progress to dependence at some time in their lives. This is typically due to
factors such as sociodemographic and psychopathological factors (Flórez-Salamanca et al.,
2013). All these factors make it challenging to identify a set of universal genetic and
environmental factors that drive the risk to develop AUD (Reilly et al., 2017).
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4. Known genetic contributions influencing risk for AUD.
A large body of research has been done to examine environmental and genetic factors
contributing to AUD to understand how people develop this disorder (Edenberg and Foroud,
2013). Multiple strategies have been used to identify genes and genetic pathways that may
influence various aspects of alcohol abuse. Since the process of addiction involves hundreds of
genes, only a few functional loci have been found to be associated with alcoholism (Ducci and
Goldman, 2008). Also, the vast majority of studies were underpowered and individual genes
tend to have small effects, making the unambiguous identification of associated genes very
challenging. Two known genes that have been associated with alcohol abuse encode the
alcohol metabolizing enzymes ALDH2 and ADH1B. These genes were the first genes to have
been associated with alcoholism because their molecular mechanism involves breaking apart
alcohol molecules in the liver, making its influence to alcoholism very convincing (Ducci and
Goldman, 2008).
Multiple large population addiction studies using GWAS (Genome-Wide Association
Studies) have revealed hundreds of genes that are associated with alcohol-related behaviors. A
GWAS study of over 500,000 individuals was conducted from the Alcohol Use Disorder
Identification Test (AUDIT). This test is a screening tool designed to identify hazardous alcohol
use in the past year (Sanchez-Roige et al., 2019). This test consists of 10 items across three
dimensions of alcohol consumption (AUDIT-C) and dependence and harmful alcohol use
(AUDIT-P) (Sanchez-Roige et al., 2019). This study did a GWAS for both AUDIT-C and -P with a
population from BioBank and 23andMe to identify associated risk loci. The top hits from this
study include CADM2, MAPT, FUT2, SLC39A8, JACB, LINC01833, ADH1C, ADH1B, KLB, and GCKR.
-3-

These top hit genes had the strongest association with AUDIT scores and included the alcohol
metabolism genes (Sanchez-Roige et al., 2019). This study concluded that AUDIT scores in
certain population-based cohorts can be used to explore the genetic basis of both alcohol
consumption and AUD (Sanchez-Roige et al., 2019).
Another GWAS study of tobacco and alcohol use using 1.2 million individuals was
recently conducted. This study found 566 variants and 406 loci that are associated with multiple
stages of alcohol and tobacco use (Liu et al., 2019). The top hits for alcohol use include genes
such as MEF2C, FUT1, CGKR, CADM2, ADH1A, MAPT, SPNS1, AUTS2. They also found that
alcohol phenotypes are negatively correlated with health conditions, and increased genetic risk
for alcohol use is associated with lower disease risk (Liu et al., 2019). However, since substance
use is embedded in a large complex of mechanisms and relationships between genes and
environment, caution must be used in drawing any conclusions (Liu et al., 2019). The findings
from this GWAS analysis represent a major step forward in understanding these multi-factorial
addiction diseases (Liu et al., 2019).
A different GWAS study on problematic alcohol abuse (PAU) was done to identify risk
genes of a population of over 400,000 European ancestry individuals (Zhou et al., 2020). This
study identified 29 independent loci, with 19 of them being novel genes. Some of the genes
from this list include: PDE4B, GCKR, SIX3, VRK2, THSD7B, IRS1, CADM2, KLB, ADH1B, ADH1C,
SLC39A8, DPP6, PENK, UNC5B, FUT2 (Zhou et al., 2020). The study also revealed that PAU was
genetically correlated with 139 phenotypes, the top correlation being neuropsychiatric traits.
Overall, this study was able to implicate numerous genes in alcohol abuse (Zhou et al., 2020).
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All three of the studies reviewed here were interested in determining loci that were
associated with various aspects of alcohol abuse. Some of the genes that were listed in all three
of the individual studies include FUT2, CADM2, KLB, ADH1B, ADH1C and GCKR, strongly
suggesting that these genes would be appropriate for further study. These three studies were
also able to determine genetically correlated phenotypes such as a neuropsychiatric traits,
consumption and abuse. By completing these large GWAS studies, we can use the results to
study certain genes and pathways in model organisms to better understanding alcohol-related
behaviors.
B. Drosophila melanogaster as a model for investigating behavioral responses to alcohol
1. Conservation between humans and flies
Model organisms have emerged as powerful genetic experimental platforms for
investigating genes influencing alcohol-related behaviors and molecular mechanisms similar to
those in humans. Specifically, the fruit fly, Drosophila melanogaster is a low-cost, fastreproducing model organism used to study the genes associated with behavioral responses to
alcohol (Grotewiel and Bettinger, 2015). Flies are used to study alcohol-related behavior
because of the similar molecular mechanisms shared with humans, specifically, the major
molecular machinery that controls the nervous system (Chan et al., 2015). Behavioral responses
to ethanol are also conserved in humans and flies (Chan et al., 2015; Engel et al., 2019). Low
doses of alcohol result in increased psychomotor activity in humans and locomotor behavior in
flies, while higher doses result in sedation in both species (Grotewiel and Bettinger, 2015). Flies
can also develop a tolerance and withdrawal symptoms to ethanol over time in a manner that is
phenotypically similar to that in humans (Adkins et al., 2017). Consumption of ethanol can
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result in any of the above behavioral changes in both humans and flies (Engel et al., 2019).
There are a number of behavioral assays that can be performed on flies to measure their
different types of behavioral responses to ethanol exposure.
2. Current approaches used to investigate genetic contributions to alcohol-related behavior in
flies
Flies have multiple behavioral responses to ethanol including sedation, locomotor
activation, withdrawal, tolerance, and consumption. Ethanol sedation is used to measure initial
sensitivity of the fly toward ethanol exposure (Sandhu et al., 2015). Flies are exposed to ethanol
vapor (this increases their internal ethanol as it would in humans when drinking) and then the
number of flies that become sedated during the ethanol exposure is recorded. These raw data
are then converted into a percent active as a function of time. The percent active can further be
quantified as Sedation Time 50 (ST50, the time required for 50% of the flies to become sedated.
(Sandhu et al., 2015) as a routine measure of ethanol sedation in flies. Longer ST50 values
indicate resistance to sedation, whereas shorter ST50 values indicate increased sensitivity to
sedation.
Chronic or repeated exposure of humans to alcohol can lead to the development of
tolerance, defined as a blunted response during a prolonged or subsequent discrete exposure
to the drug. Flies also develop tolerance to alcohol when measured with sedation, postural
control or locomotor activation studies (Wolf et al., 2002). Flies also prefer to consume ethanolcontaining food compared to food without ethanol and, importantly, this preference increases
during repeated exposure of flies to food laced with ethanol. The two-choice Capillary Feeder
(CAFE) assay is used to measure ethanol consumption and preference. Flies are allowed to feed
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from two different capillaries, one with nonethanol liquid food and the other with liquid food
containing ethanol. Ethanol preference is quantified by calculating a preference index (PI). The
PI is defined by ethanol consumption [(ethanol consumption - nonethanol consumption)/total
consumption]. The PI will vary between -1 and +1, positive values indicating ethanol preference
and negative values indicating repulsion (Devineni and Heberlein, 2009). The CAFE assay
models several features of human addiction including flies increasing ethanol consumption and
preference overtime, voluntary consumption leading to pharmacologically relevant ethanol
concentrations in the flies, flies overcoming an unpleasant stimulus to obtain ethanol, and flies
exhibiting withdrawal symptoms when deprived from ethanol (Devineni and Heberlein, 2009).
In humans, the more we consume alcohol, the higher tolerance we build up to the
physiological and behavioral response to a particular dose of alcohol (Scholz et al., 2000). Flies
can exhibit a similar response when exposed to ethanol multiple times. Adult Drosophila can
develop tolerance to the sedating and locomotor impairing effects of ethanol. Rapid tolerance
is a phenomenon defined as a reduction in the intensity of the effects of ethanol upon repeated
exposure (Berger et al., 2004). To measure rapid tolerance, flies are first exposed to ethanol to
become sedated, are allowed a period of recovery in the absence of ethanol, and are then
subjected to ethanol sedation a second time (Sandhu et al., 2015). An ST50 is calculated for
both the initial exposure and for the second exposure to determine if the flies develop a
tolerance to ethanol, evidenced by an increased ST50 during the second exposure.
Alcohol consumption can also have an effect on locomotor activity in flies. In order to
observe fly locomotor activity, flies are exposed to ethanol vapor and video-recorded (Wolf et
al., 2002). The motion of individual flies is then determined in a combination of computational
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methods (Wolf et al., 2002). These methods quantify locomotion of flies in an automated
matter. Ethanol affects flies by dynamically altering several parameters of walking behavior
during the course of exposure. Acute ethanol exposure increases a fly’s walking speed and
turning, whereas prolonged exposure leads to loss of postural control and sedation (Wolf et al.,
2002).
Flies can also develop withdrawal symptoms. Acute alcohol treatment impairs the
performance of fly larvae in a simple associative learning and memory assay (Robinson et al.,
2013). This assay can be used to measure signs of withdrawal (Robinson et al., 2013). Larvae are
chronically fed alcohol-containing food, they acquire tolerance, and then behave as if they have
not been exposed to alcohol. However, removal of the alcohol-containing food from the larvae
resulted in withdrawal, and nervous system hyperexcitability (Robinson et al., 2013). This
suggests that flies can adapt to become dependent on alcohol and show signs of withdrawal.
3. Genetic manipulations in flies
There are different strategies used to study the underlying genetic mechanisms that
may influence a fly’s behavioral response to alcohol. Broadly, there are two different general
strategies to manipulate a fly’s genome. The first is a transgenic strategy including the GAL4UAS system and the GeneSwitch inducible expression system. The second strategy is to mutate
endogenous genes in the fly genome. Mutations can be caused by chemical or other mutagens,
chromosomal deletions, or transposon insertions. Both of these general strategies have proven
successful in studying the role of fly orthologues of human genes that may influence AUD.
The GAL4 system is a method for ectopic gene expression that allows the activation of
(in principle) any gene in different tissue and even cell-specific patterns. An advantage to this
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system is the separation of the GAL4 protein from its target gene in distinct transgenic lines.
This ensures that the target gene is largely silent except in the presence of GAL4 (Southall et al.,
2008). The GAL4 system is highly flexible, providing a versatile tool for controlling ectopic
expression both spatially and temporally. This system can be used to activate gene expression,
express altered forms of proteins, and toxins for cell ablation or inhibition of cellular function
(Duffy, 2002). It is also important to note that this system can be used to express RNAi (RNA
interference).
GAL4 is a gene expressed by, identified in, and cloned from yeast, Saccharomyces
cerevisiae, as a regulator of genes induced by galactose that has been well studied for over 30
years (Duffy, 2002; Southall et al., 2008). The 881-amino acid GAL4 protein can be separated
into a DNA binding domain and an activation domain, which can function independently of each
other. The GAL4 protein binds a 17-nucleotide sequence called the Upstream Activation
Sequence (UAS). The separation of the GAL4 protein from the UAS-gene of interest in
independent transgenic lines confers many advantages on the GAL4 system (Duffy, 2002;
Southall et al., 2008) . For example, a single UAS-gene can be analyzed in multiple tissues at
several different time points through the use of different GAL4 drivers, and a single GAL4 driver
can be used to express several different UAS-transgenes in separate studies (Duffy, 2002;
Southall et al., 2008). Since the UAS construct is largely silent in the absence of GAL4, viable
transgenic lines encoding toxic or apoptotic proteins can be generated in order to further study.
This ability to target gene expression to different tissues and cells makes this a powerful tool for
studying not only development and physiology of the fly, but also the genetic mechanisms that
underlay alcohol-related behaviors in flies.
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Another transgenic strategy used to alter gene expression in Drosophila melanogaster is
the GeneSwitch system (GS). This is an inducible gene expression system that uses a modified
GAL4-UAS activation system (Osterwalder et al., 2001). This system was developed so
transgenes could be expressed after post embryonic development, or in adult flies only
(Osterwalder et al., 2001). Here, the GAL4 protein remains in an inactive conformation until the
presence of the drug, mifepristone (RU486). The mifepristone allows the GAL4 protein to
change from its inactive conformation to its active conformation, then the protein can bind to
the UAS sequence to activate a gene of interest (or an RNAi). The mifepristone can be
administered to the flies by either feeding or immersing the animals in a solution containing the
drug (Nicholson et al., 2008). By varying the timing and dosage of drug being administered to
the flies, the expression of the transgene can also be controlled. This system, similar to the
GAL4-UAS system, can also be used to study the genetic mechanisms of alcohol-related
behaviors at different stages of a fly’s lifecycle, making this transgenic system a powerful tool
for connecting developmental processes to, or dissociating them from specific behavioral
responses to alcohol.
Another inducible transgenic strategy for studying genes in Drosophila is the tetracycline
inducible system. This system is not as frequently used as the GeneSwitch inducible system, but
still has a number of advantages (Stebbins et al., 2001). This system relies on the specific, highaffinity binding of the Escherichia coli Tet repressor protein (TetR) to the Tet operator (TetO).
The tetracycline operator (TetO) is bound by either the tetracycline repressor protein (TetR) or
by a tetracycline repressor mutant (rTA) (Osterwalder et al., 2001). When flies are exposed to
doxycycline, the transgene is rapidly induced in adult flies, larvae, and embryos. It is also
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possible to modulate gene induction by controlling the dosage of doxycycline in the food
(Stebbins et al., 2001). These techniques are conceptually powerful tools, but have the practical
limitation in Drosophila that new tissue specific TetR or rTA drivers as well as tetO responder
lines need to be generated (Osterwalder et al., 2001). Although, this system can also be used to
study the genetic mechanisms of alcohol-related behavior in flies, it was developed around the
same time as GS, but it was the GeneSwitch inducible system that took off in the Drosophila
field.
RNAi interference (RNAi) is an endogenous cellular mechanism triggered by expression
of double stranded RNA (dsRNA), which leads to the degradation of homologous RNA
molecules (Heigwer et al., 2017). Upon introduction of dsRNA, a complex including the DICER
protein is formed that cuts the duplex RNAs into 21-nucelotide fragments. One strand of the
dsRNA, called the guide strand, will bind an argonaute protein. The guide strand plus the
argonaute protein will form a complex called RNAi-induced silencer complex (RISC). This
complex will bind to the complementary mature mRNA strand and cleave that portion of
mRNA, that portion is then degraded (Heigwer et al., 2017). This strategy will largely silence the
target gene. In order to activate RNAi in Drosophila melanogaster, most RNAis are under UAS
control. The RNAi can be expressed using the GeneSwitch or GAL4-UAS systems described
above.
Mutations of genes are also another genetic manipulation used in Drosophila. Two main
approaches are typically used: transposon insertions and chemical mutagenesis. Mutagenesis
via insertions of engineered transposons can be used to analyze gene function and regulation. A
transposon is a mobile DNA element that once inserted in the genome can disrupt gene
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function and/or expression (Bellen et al., 2011). Transposons can also be remobilized to
generate other useful mutations in the gene region where it resides through the processes of
local jumping or imprecise excision (Bellen et al., 2011). Collections of insertion mutations have
been created with genetic markers such as eye color, body color, drug resistance, etc. allowing
multiple insertions to be manipulated (Bellen et al., 2004).
Chemical mutations have the major advantage of being unbiased and sometimes
permitting the generation of allelic series. Chemical mutagenesis with ethyl methane sulfonate
(EMS) is a powerful approach for generating mutant strains of cells or organisms for studying all
biological processes. In Drosophila, a causative DNA lesion for a specific phenotype can be
identified by mapping of the mutant locus using visible genetic markers that span the genome
(Cingolani et al., 2012). All mutation strategies and transgenic strategies described can be used
to manipulate Drosophila orthologs of human genes known to be associated with AUD.
4. Genes known to influence alcohol-related behaviors in Drosophila melanogaster
Multiple studies in flies have significantly contributed to our understanding of
molecular-genetic mechanisms that influence alcohol-related behaviors (Grotewiel and
Bettinger, 2015). Approximately 150 genes in flies with roles in behavioral responses to alcohol
have been described, however only a few genes will be discussed here. These genes have been
highly studied in flies to make them candidate genes that may influence AUD in humans. These
include: Insulin signaling pathway genes, AUTS2 ortholog, Heat shock proteins, the XRCC5 gene
and the gene at the core of my thesis project, Mef2.
The molecular genetic analysis of flies have demonstrated the existence of the
extremely well conserved insulin signaling pathway (Garofalo, 2002). The role of insulin
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signaling in the control of lifespan, reproduction, and metabolism has also been revealed by
genetic studies of this pathway in flies. Studies using loss of function (LOF) mutants in the InR
genetic pathway (fly ortholog pathway for insulin signaling ) have revealed that this pathway in
the nervous system influences sensitivity to the intoxicating effects of ethanol (Corl et al.,
2005). Studies on the insulin signaling pathway in flies suggests an evolutionarily conserved role
in regulating the response of the nervous system to intoxicating drugs, giving a possible
candidate pathway to study more in depth in other model organisms and humans to
understand the genetics of AUD (Corl et al., 2005).
Flies have also been used to explore the role of tay, the fly ortholog gene to human
AUTS2. A single nucleotide polymorphism (SNP) in the intron region of AUTS2 was found in a
GWAS study looking at alcohol consumption(Engel et al., 2019). AUTS2 was also studied when
comparing mice lines bread for alcohol preference (HAP1) with low alcohol preferring mice
(LAP1) (Mulligan et al., 2006; Schumann et al., 2011; Engel et al., 2019). Reduced expression of
the fly ortholog, tay, a regulator of the epidermal growth factor (EGFR) (Engel et al., 2019),
decreased ethanol sensitivity (Schumann et al., 2011). The genetic studies in flies suggest that
the InR and tay/AUTS2 genes might influence AUD in human via regulation of ethanol sedation
sensitivity.
Microarray experiments have been used in the past to determine changes in gene
expression following ethanol exposure in flies. One of the changes seen in these experiments
involves the regulation of genes encoding heat shock proteins (HSP). Out of these genes, hsp26
is the most strongly regulated HSP-encoding genes (Awofala et al., 2011). hsp26 encodes an
HSP that has been shown to be temperature-regulated in yeast and regulates aging and
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oxidative stress in flies (Awofala et al., 2011). Previous research has demonstrated that hsp26 is
required for development of tolerance to ethanol. Further studies of the role in hsp26 in the
nervous system of flies could provide more information for understanding the development of
tolerance and dependence in alcoholics (Awofala et al., 2011). Investigating the pathway of
hsp26 could ultimately lead to a better understanding of genes involved in tolerance and
potentially AUD.
Other genes that are known to influence ethanol-induced behaviors in flies include
Icarus (ics), which encodes Ras suppressor 1 (Rsu1) (Ojelade et al., 2015), and Mef2 (myocyteenhancer factor 2), a MADS-box transcription factor (Potthoff and Olson, 2007) (see next
section). When genetic manipulations are made to either of these genes, there is a significant
change in the fly’s behavioral response to ethanol. Drosophila lacking Rsu1 show reduced
sensitivity to ethanol-induced sedation. A more recent study did a GWAS of genes that are
associated with alcohol susceptibility in humans and found the XRCC5 gene. Further testing
with the Drosophila melanogaster ortholog, Ku80, found that when flies were exposed to
ethanol their initial sensitivity significantly decreased in Ku80 mutants (Juraeva et al., 2015).
There are over 150 other Drosophila genes that are also known to influence ethanol-induced
behavioral responses, and they all play a part in understanding the genetic mechanisms
underlying AUD.
C. Myocyte Enhancer Factor 2 (Mef2)
1. Mef2 in humans and Drosophila melanogaster
Mef2 (myocyte enhancer factor-2) encodes a family of transcription factors with a
variety of different functions. MEF2 proteins belong to the evolutionarily ancient MADS family
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(Potthoff and Olson, 2007). There are four mammalian genes, Mef2 A, B, C and D. Of the four
mammalian genes, Mef2A, C, and D can be alternatively spliced to produce transcripts and
proteins which may have significantly different functions (Brand, 1997). These different
functions could play a role in development of skeletal, cardiac, and smooth muscle cells (Black
and Olson, 1998). MEF2 proteins bind to consensus DNA sequence YTA(A/T)4TAR as homo-or
heterodimers.
The MEF2 protein family plays central roles in a variety of physiological processes
including development of the nervous system and muscle development (Pon and Marra, 2016;
Chen et al., 2017). This family is also implicated in human diseases such as liver fibrosis,
cancers, and neurodegenerative diseases (Chen et al., 2017). For example, MEF2B and D are
involved in maintaining Epstein-barr virus (EBV), which is known as one of the nine human
herpesvirus types and drives resting B cells to continuously proliferate infected cells (Kempkes
and Robertson, 2016). EBV infection can be linked to several malignancies including Burkitts’
lymphoma, Hodgkin’s lymphoma, gastric carcinoma, and many more human diseases (Kempkes
and Robertson, 2016).
In Drosophila melanogaster, there is only one orthologue of Mef2 gene. Fly Mef2 is
critical for the differentiation of muscle cell lineages and is essential for viability of the flies
(Crittenden et al., 2018). Mef2 is also essential for the formation of mushroom bodies in the
embryonic brain and for normal development of wings in adults. Mef2 also transmits clock
information to machinery involved in neuronal remodeling, which contributes to locomotor
activity rhythms and circadian behavior (Sivachenko et al., 2013).
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2. Mef2 influences ethanol sedation in Drosophila melanogaster
Previous studies indicate that low initial sensitivity to alcohol may be a risk factor for
later alcohol abuse. A 12 question alcohol form called “The Self-Rating Effects (SRE) of alcohol”
was developed to help predict if a person has a low response to alcohol (Schuckit et al., 1997).
Dr. Alexis Edwards conducted a meta-analysis of two population-based genome-wide
association studies (GWAS) of SRE. This analysis interrogated over 18,000 genes, 37 of which
had a nominally significant p value (pgene<0.001) for SRE. Of those 37 genes, 29 had orthologues
in Drosophila (Schmitt et al., 2019). Nine human genes were selected for further testing in
Drosophila based on previous research suggesting they might be related to alcohol use or
misuse.
The human genes APP, ATG5, BORCS8, MEF2B, GPD2, ISL1, MEF2B, PCDH15, and,
SFSWAP are orthologs to 12 Drosophila genes. RNAi reagents were obtained from public stock
centers to manipulate the most conserved fly genes (Schmitt et al., 2019). These genes were
tested by expressing RNAi targeting each gene in neurons using elav-GAL4 and assessed ethanol
sedation in adults. Three RNAi transgenes against Mef2 (two with the same target sequence)
increased ST50 values compared to the genetic controls (Schmitt et al., 2019). These results led
us to believe that other genes associated with Mef2 may likewise play a role in ethanol
sedation.
D. Significance
As mentioned in section A, AUD has many negative consequences on people all over the
globe. This includes premature death or preventable death, mental health effects, decrease in
productivity and the development of disease states (Edenberg and Foroud, 2013). Current
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treatment options include individual or group psychotherapies and some prescription drug
therapies (Kranzler and Soyka, 2018). However, some patients who initially achieve abstinence
from drinking will eventually relapse to alcohol consumption within a year of receiving
treatment (Johnson and Ait-Daoud, 1999). Although these are viable treatment options, there is
still a large gap in the knowledge of understanding and treating AUD.
AUD is a complex disease with both an environmental component and a genetic
component. Drosophila melanogaster is a powerful tool for investigating the biology of genes
implicated in human AUD. Additionally, flies can be used to identify novel candidate genes for
roles in human AUD. These studies will not only help us to understand the molecular and
genetic mechanisms of this disease, but these mechanisms studied in flies can eventually be
translated back to humans to further study. Researchers will then be able to better diagnose
and potentially treat patients with AUD.
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Chapter 2-Materials and Methods
A. Fly husbandry and stocks
Flies were cultured in an environmental chamber with a 12-hour light/dark cycle. They were
maintained at 25oC and 60-65% relative humidity. Flies were grown on Drosophila food medium
containing 10% sugar, 3.3% cornmeal, 2% yeast, 1% agar, 0.1 g/L ampicillin, 0.125 g/L
chloramphenicol, 2 g/L tegosept, 0.02 g/L tetracycline, and live yeast.
w[A] (stock #5905), transposon spin mutant stocks, spin RNAi (stock #27702), ph-d (stock
#31190), and GeneSwitch (GS) lines were all obtained from Bloomington Drosophila Stock
center (BDSC, Bloomington, IN). w[VDRC], and Mef2 RNAi (stock #v15550) were obtained from
the Vienna Drosophila RNAi center (VDRC, Vienna, Austria). All RNAi lines, transposon, GS, and
other lines are listed in Table 1.
Genotype

Stock #

Description

Source

w[1118]

5905

lab control strain

BDSC

elav-Gal4 w[A]/FM7B

NA

neuronal driver

P. Bhandari

w[VDRC]

NA

VDRC control strain

VDRC

w[1118][A]; CyO/Sp[A]; 3[A]

NA

balancer

Lauren Thomas

w[1118];2]VDRC];v15550[VDRC]

v15550

Mef2 RNAi

VDRC

y[1] v[1]; P{y[+t7.7] v[+t1.8]=TRiP.JF02782}attP2

27702

spin RNAi

BDSC

y[1] v[1]; P{y[+t7.7] v[+t1.8]=TRiP.JF01705}attP2

31190

ph-d RNAi

BDSC

y1 v1; P{TRiP.HMS02042}attP40

40875

tau RNAi

BDSC

y1 v1; P{TRiP.HM05101}attP2

28891

tau RNAi

BDSC

w1118; P{GD8682}v25023

v25023

tau RNAi

VDRC

w1118; P{GD8682}v25024

v25024

tau RNAi

VDRC

w1118; P{GD10150}v25666

v25666

tau RNAi

VDRC

w1118; P{GD10150}v25667

v25667

tau RNAi

VDRC

P{KK109359}VIE-260B

v101386

tau RNAi

VDRC

P{TRiP.HMS00445}attP2

32447

Frl RNAi

BDSC

w1118; P{GD10799}v34412

v34412

Frl RNAi

VDRC

w1118; P{GD10799}v34413

v34413

Frl RNAi

VDRC

P{KK101703}VIE-260B

v110438

Frl RNAi

VDRC

PBac{fTRG01118.sfGFP-TVPTBF}VK00002

v318758

Frl RNAi

VDRC

w1118; P{GD10457}v21446

v21446

Frl RNAi

VDRC

P{KK110613}VIE-260B

v102402

CG6770 RNAi

VDRC
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w1118; P{GD13710}v35825

v35825

CG6770 RNAi

VDRC

y[1] v[1]; P{y[+t7.7] v[+t1.8]=TRiP.JF02715}attP2

27561

CG6770 RNAi

BDSC

w1118 P{GD1650}v3229

v3229

spin RNAi

VDRC

w1118; P{GD1650}v46030

v46030

spin RNAi

VDRC

P{KK104813}VIE-260B

v105462

spin RNAi

VDRC

P{TRiP.GL01585}attP2

43975

chrb RNAi

BDSC

P{KK109191}VIE-260B

v105757

chrb RNAi

VDRC

PBac{fTRG00853.sfGFP-TVPTBF}VK00002

v318693

chrb RNAi

VDRC

w1118; P{GD9925}v25506

v25506

Scyl RNAi

VDRC

w1118; P{GD9925}v25504/CyO

v25504

Scyl RNAi

VDRC

y1 v1; P{TRiP.HMJ02221}attP40

42564

stv RNAi

BDSC

w1118; P{GD10796}v34408

v34408

stv RNAi

VDRC

w1118; P{GD10796}v34409/TM3

v34409

stv RNAi

VDRC

y1 v1; P{TRiP.JF01392}attP2

31608

ph-p RNAi

BDSC

w1118; P{GD4480}v10679

v10679

ph-p RNAi

VDRC

P{KK108787}VIE-260B

v100811

ph-p RNAi

VDRC

35207

ph-p RNAi

BDSC

y[1] sc[*] v[1] sev[21]; P{y[+t7.7]
v[+t1.8]=TRiP.GL00083}attP2/TM3, Sb[1]
y[1] sc[*] v[1] sev[21]; P{y[+t7.7]
v[+t1.8]=TRiP.HMS00082}attP2

33669

ph-p RNAi

BDSC

P{TRiP.HMS05292}attP40

63018

ph-d RNAi

BDSC

P{VSH330529}attP40

v330529

ph-d RNAi

VDRC

Tubulin GS

NA

ubiquitous GS driver

Scott Pletcher

P{w[+mW.hs]=Switch2}GSG3315-1, w[*]
y[1] w[*];
P{w[+mW.hs]=Switch2}betaTub56D[GSG5793]/CyO

59949

putative neuronal GS

BDSC

40333

putative neuronal GS

BDSC

w[*]; P{w[+mW.hs]=Switch2}GSG3763

40286

putative neuronal GS

BDSC

P{w[+mW.hs]=Switch2}GSG5970, w[*]

40251

putative neuronal GS

BDSC

w[*]; P{w[+mW.hs]=Switch2}GSG4948

40294

putative neuronal GS

BDSC

w[*]; P{w[+mW.hs]=Switch2}GSG4784/CyO

40283

putative neuronal GS

BDSC

y[1] w[*]; P{w[+mC]=elav-Switch.O}GSG301

43642

putative neuronal GS

BDSC

w[1118]; P{w[+mC]=MB-Switch}3/TM6C, Sb[1]
P{w[+mGT]=GT1}ph-d[BG02139] w[1118]

81013

putative neuronal GS

BDSC

12551

ph-d transposon

BDSC

Mi{ET1}ph-d[MB01363] w[1118]
y[1] w[67c23]; P{w[+mC]
y[+mDint2]=EPgy2}spin[EY08566]

23076

ph-d transposon

BDSC

16431

spin transposon

BDSC

y[1] w[67c23]; P{w[+mC]
y[+mDint2]=EPgy2}spin[EY10097]
y[1] w[67c23]; P{w[+mC]=lacW}spin[k09905]/CyO

19895

spin transposon

BDSC

10948
28838

y[1] w[*]; P{w[+mC]=UAS-GFP::lacZ.nls}30.1

6452

Nrv2-Gal4:UAS-GFP

NA

spin transposon
UAS-Tetanus Toxin light
chain
UAS-LacZ with nuclear
localization signal
neuronal UAS-GFP

BDSC

w[*]; P{w[+mC]=UAS-TeTxLC.tnt}G2

Table 1: Fly stocks used.
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BDSC
BDSC
Paul Salvaterra

B. Backcrossing
All transposon lines (stocks #12551, 23076, 10948, 19895, 16431) for spin and ph-d were
backcrossed to w[A] for seven generations to standardize the genetic background. Flies with
red eyes or green eyes (ph-d stock #23076) were selected for the next generation in the
backcross. All spin lines (stocks # 16431, 10948, 19895) were balanced to CyO/Sp w[A].
C. Ethanol sedation experiments
Flies were collected in groups of 11 by a single sex under brief CO2. Collected flies recovered
overnight in upside-down, non-yeasted food in the environmental chamber (25oC, 60-65%
humidity). Fresh 85% ethanol was made no more than one week before the experiments and all
ethanol sedation studies were done at 20-23oC with relative humidity between 55-65% and
standard laboratory lighting. To initiate ethanol sedation studies, flies were transferred to
empty food vials and sealed with a cotton Flug. Sedation time 50 (ST50) values, the time it takes
for 50% of the flies in the individual vials to become sedated, was determined by exposing the
flies to 85% ethanol vapor and assessing the number of sedated flies at 6-min intervals. All vials
were tested in groups of four, by pouring the 85% ethanol every five seconds within each group
and testing one group per min over a period of six min as described (Chan, 2013; Sandhu et al.,
2015). The experimenter was blind to all genotypes during the experiments.
D. Immunohistochemistry and imaging
Brains from adult females flies for desired genotypes were dissected in PBT (100 mM
Phosphate buffer, pH 7.2, with 0.03% (v/v) triton X-100) under a dissecting microscope. Brains
were then fixed in 1.5 mL snap cap tubes containing 4% paraformaldehyde for 20 min at room
temperature on a rotator. Fixed brains were washed three times with PBT and blocked with 5%
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normal goat serum (NGS). To assess spin expression, brains were incubated in primary antibody
(5% NGS, mouse anti-elav and rabbit anti-SPNS2) for 48 hours at 4oC on a rotator. Brains
incubated in the primary antibody serum were then washed three times with PBT and
incubated in secondary antibody serum (5% NGS, chicken-anti Rabbit, Alexa 647, Goat antimouse, Alexa 488) for another 48 hours at 4oC on a nutator. Brains were then washed three
times with PBT and mounted onto microscope slides using SlowFade (Invitrogen by Thermo
Fisher scientific EU, Oregon). This follows the protocol as described (Wu and Luo, 2006). Images
of the brains were captured and collected using a Zeiss LSM 700 confocal microscope (Carl Zeiss
Microscopy, LLC, Thornwood, NY) housed in the VCU Department of Anatomy and
Neurobiology Microscope Facility. All images were taken using a 10X objective with a numerical
aperture of 0.3, with a pin hole of one Airy disc Unit. The microscopy settings were optimized
from control flies (spin RNAi transgene control flies). The same settings (gain, offset, power)
were used in all images of different genotypes. All images were processed using Image J
(National institute of health; Bourne and Bourne, 2010).
E. PCR and sequencing
Standard PCR methods was used for all experiments. All PCR reactions contained dNTPs,
Dream Green Taq buffer, and Dream Taq polymerase according to the manufacturer’s
instructions (thermoscientific, Waltham, MA). The BioRad c1000 thermocycler (BioRad,
Hercules, CA) was used for all PCR amplification with a temperature gradient (70.8, 68.7, 65.6,
61.7 oC). The PTC-100 programmable thermal controlled (MJ Research Inc., San Francisco, CA)
was used for all other PCR amplification reactions. Primers used for each PCR reaction are listed
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in Table 2. GeneWiz (South Plainfield, NJ) and SnapGene Viewer (Chicago, IL) was used for
sequencing and analysis.
transposon
EY10097

k09905

EY08566

P element

sense/antisense

sequence 5' to 3'

product length (estimate)

fwd

GAG TTC CCG TTT CTC TGT GTG C

234 bp

rev

TGT CCG TAT CCG AGG GCA TC

172 bp

fwd

GTG TGT CAT TGT TGT TGC TGC TGC

163 bp

rev

CCT CGT CAA TAA CTG TAA GCC GAT C

194 bp

fwd

TGC CGG CGA TAA GCG AAC C

332 bp

rev

CAC TCA AGA ATT TCG GGA GCA AAC

175 bp

--

CGACGGGACCACCTTATGTTATTTCATCATG

--

Table 2: Primers used in section 3 of results (chapter 3).
F. Statistical analyses
All statistical analyses were done on GraphPad Prism (GraphPad Software, San Diego, CA).
Bonferroni multiple comparisons, one-way ANOVA, and unpaired T-tests were used as
appropriate in accordance with the experimental design.
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Chapter 3-Genetic Analysis of spin, a candidate gene downstream of Mef2
A. RNAi-based screen of Mef2-bound genes for a role in ethanol sedation
Introduction
The Drosophila ortholog to MEF2B, which is shown to be associated with SRE, is Mef2
(myocyte enhancer factor-2). Mef2 belongs to a family of MADS-box transcription factors
(MCM1, agamous, deficiens, serum response factor). These transcription factors play multiple
roles in myogenesis and morphogenesis in Drosophila melanogaster (Black and Olson, 1998).
Central to my thesis project, Mef2 plays a significant role in ethanol sedation (Schmitt et al.,
2019). This led us to hypothesize that genes bound by Mef2 might also impact ethanol
sedation.
A previous study of alcohol tolerance in Drosophila was interested in genes that change
a fly’s response to ethanol. The researchers screened a number of genes and found that flies
with altered Hr38 had a statistical significant change in ethanol tolerance and preference
(Adhikari et al., 2019). The researchers also found that mammalian homologs of Hr38 are
transcriptionally regulated by Mef2. From there they wanted to know if ethanol upregulates
Hr38 through Mef2 to promote an ethanol-response phenotype. They found that ethanol
activates Mef2 to induce Hr38 (Adhikari et al., 2019). Previous studies in our lab found that
Mef2 RNAi knockdown in neurons as well as mutations in Mef2 made flies resistant to ethanol
sedation without a change in ethanol rapid tolerance (Schmitt et al., 2019). Since Mef2 binds
342 genes (Sivachenko et al., 2013) and the lab’s previous experiments demonstrate that Mef2
influences ethanol sedation, we hypothesized that one or more genes regulated by Mef2 may
also influence ethanol sedation. The goal of my project was to begin testing this hypothesis.
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Results
Identifying Mef2-bound genes related to alcohol-related behavior in flies
A GSCAN (GWAS & Sequencing Consortium of Alcohol and Nicotine use) of the 342
genes bound by Mef2 in flies was done to determine if any of the human orthologues of these
genes are associated with gene expression changes related to alcohol consumption. Of those
342 genes, 15 had evidence of being nominally associated with gene expression related to
alcohol consumption (Baccanu, unpublished). I was able to identify 36 RNAi transgenes
targeting nine of those genes in flies (Table 3). I then determined whether neuronal expression
of the RNAis targeting the nine genes led to an ethanol sedation phenotype in flies.
Testing Mef2-bound genes in ethanol sedation
I used the elav-Gal4 driver to express the RNAi transgenes in neurons and then
determined whether expression of the RNAi transgenes influenced ethanol sedation. Flies
expressing an RNAi transgene targeting spin (JF02782) were resistant (i.e. had higher ST50
values, red bar) than control flies with the elav-Gal4 driver (black bar) or the JF02782 RNAi
transgene alone (grey bar) (Figure 1A, B). I confirmed these results by repeating the experiment
with independent crosses and obtaining similar results (Figure 2A, B). Expression of other RNAi
transgenes targeting spin in neurons led to no definitive effects on ST50 values, although there
was a trend for spin v3229-expressing flies to be resistant to ethanol sedation (Table 3). Similar
to the results with spin RNAi transgenes, expression of one RNAi targeting ph-d (JF01705) made
flies resistant to ethanol sedation compared to genotype controls (Figure 1C, D), whereas
expression of two additional ph-d RNAi transgenes had no consistent effect on ST50 values
(Table 3). Neuronal expression of RNAi targeting the other genes (CG6770, chrb, Frl, ph-p, scyl,
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stv and tau) had no consistent effects on ethanol sedation in flies relative to control strains
(Table 3). Thus, of the 36 RNAi transgenes tested, one targeting spin and one targeting ph-d
altered ST50 values.
gene
spin

group
RNAi-expressing
control
control

spin

RNAi-expressing
control
control

spin

RNAi
JF02782
JF02782

ST50 (min)
48.09
30.65
34.6

statistical analysis
ANOVA
BMC
BMC

ST50 P value
0.0002
0.0002
0.0022

KK104813
KK104813

37.44
36.11
33.15

ANOVA
BMC
BMC

0.2319

RNAi-expressing
control
control

v3229
v3229

39.01
33.23
31.2

ANOVA
BMC
BMC

0.0287
0.1011
0.0215

spin

RNAi-expressing
control
control

v46030
v46030

37
36.48
31.83

ANOVA
BMC
BMC

0.0135
> 0.9999
0.0148

ph-d

RNAi-expressing
control
control

JF01705
JF01705

53.35
43.03
37.21

ANOVA
BMC
BMC

0.0009
0.0205
0.0005

ph-d

RNAi-expressing
control
control

HMS05292
HMS05292

34.61
26.35
36.03

ANOVA
BMC
BMC

0.0002
0.0011
0.9921

ph-d

RNAi-expressing
control
control

VSH330529
VSH330529

38.03
27.2
34.18

ANOVA
BMC
BMC

0.0001
< 0.0001
0.1574

CG6770

RNAi-expressing
control
control

KK110613
KK110613

28.01
25.53
28.73

ANOVA
BMC
BMC

0.3096

CG6770

RNAi-expressing
control

v35825
v35825

34.43
35.8

ANOVA
BMC

0.4926
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control

33.05

BMC

CG6770

RNAi-expressing
control
control

JF02715
JF02715

35.33
33.45
33.1

ANOVA
BMC
BMC

0.4957

Frl

RNAi-expressing
control
control

KK101703
KK101703

31.38
41.61
32.45

ANOVA
BMC
BMC

0.7154

Frl

RNAi-expressing
control
control

HMS00445
HMS00445

43.35
38.31
36.05

ANOVA
BMC
BMC

0.0507

Frl

RNAi-expressing
control
control

v34413
v34413

29.75
36.11
30.16

ANOVA
BMC
BMC

0.0007
0.0011
> 0.9999

frl

RNAi-expressing
control
control

v34412
v34412

37.79
38.15
35.21

ANOVA
BMC
BMC

0.2995

chrb

RNAi-expressing
control
control

KK109191
KK109191

33.01
26.66
32.73

ANOVA
BMC
BMC

0.1162

chrb

RNAi-expressing
control
control

GL01585
GL01585

32.61
30.36
32.05

ANOVA
BMC
BMC

0.7009

tau

RNAi-expressing
control
control

v25667
v25667

25.78
27.34
28.08

ANOVA
BMC
BMC

0.7108

Tau

RNAi-expressing
control
control

v25024
v25024

27.5
32.04
29.18

ANOVA
BMC
BMC

0.0564

Tau

RNAi-expressing
control
control

v25666
v25666

29.46
34.9
32.14

ANOVA
BMC
BMC

0.0305
0.018
0.343
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ANOVA
BMC
BMC

0.0091
0.0088
0.8974

22.29
21.75
31.54

ANOVA
BMC
BMC

< 0.0001
> 0.9999
0.0002

HM05101
HM05101

27.85
25.58
27.63

ANOVA
BMC
BMC

0.1129

RNAi-expressing
control
control

v25506
v25506

32.24
32.95
29.49

ANOVA
BMC
BMC

0.1344

stv

RNAi-expressing
control
control

HMJ02221
HMJ02221

26.56
28.85
32.41

ANOVA
BMC
BMC

0.0236
0.0144
0.515

stv

RNAi-expressing
control
control

v34409
v34409

36.63
38.56
38.94

ANOVA
BMC
BMC

0.2925

stv

RNAi-expressing
control
control

v34408
v34408

33.93
34.28
35.68

ANOVA
BMC
BMC

0.5855

ph-p

RNAi-expressing
control
control

JF01392
JF01392

42.34
41.45
35.61

ANOVA
BMC
BMC

0.0354
> 0.9999
0.0349

ph-p

RNAi-expressing
control
control

G1884
G1884

48.76
43.14
39.95

ANOVA
BMC
BMC

0.0107
0.0914
0.0064

tau

RNAi-expressing
control
control

KK109359
KK109359

31.52
42.73
34.2

tau

RNAi-expressing
control
control

v25023
v25023

lethal

tau

RNAi-expressing
control
control

HMS02042
HMS02042

tau

RNAi-expressing
control
control

scyl
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ph-p

RNAi-expressing
control
control

GL00083
GL00083

43.26
39.84
34.85

ANOVA
BMC
BMC

0.0009
0.17
0.0005

ph-p

RNAi-expressing
control
control

v10679
v10679

38.73
34.15
36.23

ANOVA
BMC
BMC

0.2251

Table 3: Mef2-bound gene screen using ethanol sedation. All RNAis for the nine Mef2-bound
genes are under UAS control and expressed using elav-GAL4. One-way ANOVA and Bonferroni
multiple comparisons (BMC) were used to analyze ST50 results.
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Figure 1: Ethanol sedation levels in flies with pan-neuronal expression of spin RNAi (A and B) and ph-d RNAi (C and D).
B) and D) ethanol sedation time courses of flies with the pan-neuronal expression of spin C) and ph-d D) RNAis. A) and
C) ST50 values derived from time courses in panels B and D. *Bonferroni multiple comparisons (BMCs), p=0.0002 (A),
p=0.005 ( C ); n=8.

- 29 -

Figure 2: Ethanol sedation levels in flies with pan-neuronal expression of spin RNAi (A and B)
and ph-d RNAi (C and D) repeated for confirmation. B) and C) ethanol sedation time courses of
flies with the pan-neuronal expression of spin C) and ph-d D) RNAis. A) and C) ST50 values
derived from time courses in panels B and D. *Bonferroni multiple comparisons (BMCs),
p=0.0162 (A), p=0.0101 ( c ); n=8.
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Discussion
spin and ph-d were two genes that showed a significant change in ethanol sedation
when the RNAi was neuronally expressed. Based on the results of this ethanol sedation screen
spin and ph-d were chosen as candidate in ethanol sedation. spin (spinster) is a late
endosome/lysosome membrane protein that works as a lysosomal sugar carrier (Kim et al.,
2017). ph-d belongs to a locus of Drosophila called polyhomeotic (ph) and is a complex locus
essential for the maintenance of segmenting flies during development (Hodgson et al., 1997).
The ph group is split into proximal (ph-p) and distal (ph-d) transcription units that are regulated
differently at the mRNA level during development as shown in previous research (Hodgson et
al., 1997). However, ph-d was dropped as a candidate gene for ethanol sedation due to its
complex locus and lack of reagents for further experiments. This leaves spin as the Mef2-bound
gene as a candidate in ethanol sedation in Drosophila melanogaster.
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B. Effects of spin transposon insertions on ethanol sedation
Introduction
Genetic mutations in genes are essential tools for analyzing gene function. The
Drosophila Gene Distribution project (GDP) has been making mutations in genes all over the
Drosophila genome. One class of mutations they make in different genes is inserting engineered
transposable elements (transposons) (Bellen et al., 2004). These transposons are inserted
within genes to disrupt gene expression, and because of this, these insertions into the genome
are one of the most versatile approaches to manipulating Drosophila genes on a genome-wide
scale (Bellen et al., 2004).
There are many categories of these transposable elements, one of these categories are
“P transposable elements” (P-element transposons). These are one of the best-studied mobile
DNA elements. The overall structure of these P-elements in Drosophila contain 31 bp terminal
inverted repeats (TIR) at the ends of the transposon (Bellen et al., 2011). P-elements can also
move around the genome with the help of the transposase enzyme within the P-element,
however, the engineered P-elements from GDP do not contain this enzyme. Instead, these
elements contain a “mini-white marker.” This is a gene that turns the flies eyes red in a mutant
background that otherwise would have white eyes. (Bellen et al., 2011) (figure 3). Since these
transposable elements are so versatile, the goal of this project is to determine if the P-elements
within the spin gene can influence ethanol sedation.
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P element DNA

Mini-white marker

Inverted repeats

10-15 kb long
Figure 3: P element transposable element (P element). The red regions at either end of the transposon DNA are
inverted repeats (~31bp in length). These repeats are the same on either side of the P element. These P
elements contain a gene called “mini-white” which turns a fly’s eye red in a white mutant background; this is
how transposons are tracked at the macroscopic level. These transposons can be anywhere from 10 to 15 kb
long.
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Results
Genotyping before backcross
Flies that contained the P-element in the spin gene were backcrossed so all flies had the
same genetic background. All flies were genotyped for the P-element transposon using PCR
with DNA that came from flies before entering the backcross and after finishing the backcross.
Genotyping using PCR involved designing primers that targeted the DNA upstream of the
transposon DNA and downstream of the transposon (figure 4). A primer was also designed to
target the inverted repeats on either end of the transposon (P-element primer). For each Pelement containing fly, two sets of reactions using different primer combinations were
performed (figure 4). The first reaction was using the primer that targeted the DNA upstream of
the transposon (forward primer) with the P-element primer (front end reaction; figure 4), and
the second reaction used the primer targeting the DNA downstream of the transposon with the
P-element primer (backend reaction; figure 4). A series of PCR reactions on the primers used
and the transposon DNA was done to verify that the results from DNA gel electrophoresis were
for the intended DNA.
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1) Design primers to target DNA around transposon

Spin/ph-d

Back end

Front end

DNA electrophoresis

3) PCR amplify Front end of the transposon and back
end of transposon

DNA electrophoresis

Figure 4: Genotyping protocol using PCR and DNA gel electrophoresis. The red upside-down triangle is how
transposons are noted with a gene’s DNA . For each transposon two primers were made to target the DNA upstream
from the transposon (fwd or front end) and DNA downstream of the transposon (rev or back end). One primer was
made for all of the P element transposons to target the inverted repeats of the transposon’s DNA. For each
transposon, two separate reactions were used to verify the reported location/determine if the transposon went
through the seven generations of backcrossing. The first reaction was using the upstream primer plus the P element
primer and the second reaction was using the downstream primer plus the P element primer.

- 35 -

Genotyping was done before backcrossing the spin P transposable element containing
flies to verify the locations of these transposons were in the reported locations (flybase.org).
Three spin transposable element containing flies were tested; EY10097, EY08566, K09905
(figure 5A). EY10097 PCR results did not have the anticipated band sizes with the front-end
reaction results in primer dimers and the back-end reaction having band sizes over 100 bp too
big. Sequencing revealed that the transposon was upstream of the reported position from
Flybase (figure 5B). EY08566 band sizes were the intended sizes, verifying the transposon was in
its correct position (figure 5C). The last transposon was K09905, and PCR revealed nonspecific
banding in the front end of the reaction along with the predicted band size. Sequencing of the
back-end reaction for this transposon revealed that the transposon was in the correct location
(figure 5D). The non-specific banding seen (figure 5B) was from a fly that was originally
balanced over the CyO chromosome. Those nonspecific bands were predicted to be the primers
binding to DNA from the Cyo chromosome.
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Figure 5: Genotyping to verify reported locations of transposons from Flybase. A) reported locations of
transposons from flybase. B) EY10097 genotyping. Primer dimers from the front-end reaction and larger than
expected bands from the backend reaction led me to believe that transposon was not in its reported position.
These reactions were sequenced to verify that the transposon was not in reported position (red triangle) but
upstream of the position by 300 bp (blue upside-down triangle. B) K00905 genotyping results before starting
backcross. Nonspecific banding may represent the primers binding onto DNA from the extra CyO chromosome.
Sequencing confirmed transposon was in reported position (red upside down triangle). C) EY08566 PCR before
backcross, bands are expected sizes confirming the reported position (red upside-down triangle).
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Backcross
The original stock flies containing the P-transposable elements in different regions of
the spin gene did not have the same genetic background, meaning that testing for an ethanol
sedation phenotype would not have resulted in data that was interpretable. As a result, these
flies had to be backcrossed to wild-type flies. In order to determine if I was collecting flies that
contained the transposon for each cross, it was important to use the mini-white marker within
each gene to track the transposon throughout the backcross (figure 3). If the flies from each
generation had red eyes, that meant they contained the mini-white marker within the
transposon. By the end of seven generations each P-transposable element fly had the desired
red eye, constituent with the transposons being tracked faithfully throughout the backcross
Genotyping after backcross
In order to verify that the transposon made it through the backcross, the same
genotyping process was done for the fly DNA that came after the backcross. All three
transposons had the similar PCR results from before the backcross, verifying that the
transposon in each fly came out of the backcross (figure 6). In transposon K09905, the
nonspecific bands seen in the front-end reaction from DNA before the backcrossed had gone
away, suggesting that those bands were the result of the CyO chromosome (figure 6C). Once all
three transposon locations were verified and came out of the backcross, I was able to test them
for an ethanol sedation phenotype.

- 38 -

Figure 6: Genotyping with PCR with DNA from flies after completion of backcrossing. A) verified locations of
all transposons of interest within the spin gene. B-D) verification that the transposon originally reported and
verified location went through the backcross. Red upside-down triangle: original reported location of
transposon from flybase. Blue upside down triangle: actual location of transposon D).
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Ethanol sedation of spin P transposable element containing flies.
Ethanol sedation of each fly line containing the transposon was compared to control
flies to determine if the transposon within the gene made the fly have an ethanol sedation
phenotype. Out of the three P-element flies, two of them gave a statistically significant change
in ethanol sedation (figure 7). This makes spin a strong candidate for influencing ethanol
sedation, particularly when coupled with the spin RNAi data in figures 1 and 2.
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Figure 7: ethanol sedation of backcrossed flies containing spin P-transposable elements. A-C) ST50
calculated from panels D-F. D-F) Time course of ethanol sedation *unpaired t-test using Bonferroni’s
multiple comparisons p<0.0001 C) p=0.0011 D); n=12.
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Discussion
Transposons are sequences of DNA inserted into a gene that can disrupt gene
expression (Bellen et al., 2004). Three different P-element transposons that are inserted into
the spin gene in different locations were backcrossed, genotyped, and tested in ethanol
sedation. Genotyping was done to determine that the reported location of the transposon in
Flybase was accurate and to determine that the transposon went through the seven
generations of backcrossing. Two different transposon insertions in spin resulted in a significant
change in ethanol sedation. These two transposons are candidate putative genetic
manipulations of spin along with spin RNAi in ethanol sedation. Further testing of spin
expression of these transposon insertion flies needs to be done to determine what the
transposon is doing on the molecular level to determine how this genetic manipulation is
affecting ethanol sedation.
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C . spin as a candidate in ethanol sedation
Introduction
spin is a gene that is bound by Mef2 that showed a statistically significant change in
ST50, making spin a candidate gene for ethanol sedation. spin (spinster) encodes a multipass
transmembrane protein that is typically expressed in glial cells (Sweeney and Davis, 2002; Kim
et al., 2017). This gene was first identified by its mutant phenotype which showed extreme
mating refusal of females in response to male courtship (Sakurai et al., 2010). The spin protein
is a late endosomal/lysosomal efflux permease for sugar carrying, and is also required in TGF-b
signaling (Sweeney and Davis, 2002; Kim et al., 2017). Previous research has shown that this
gene aids in cell death control (Sakurai et al., 2010) and helps control glial migration in the eyes
during development (Yuva-Aydemir et al., 2011). Loss of function (LOF) spin mutants led to
abnormal process of early endosome recycling and the accumulation of enlarged
autophagosome/autolysosomes, which lead to abnormal head growth during embryonic stages
of fly development (Kim et al., 2017). All these previous studies have shown that spin is
important for development in the eye, head, and for major signaling pathways such as TGF-b,
however no research has reported spin having influence on ethanol phenotypes in flies.
While spin and its mutants have shown phenotypes in mating behavior and
development, no research has been done on spin’s influence on ethanol sedation. My previous
ethanol sedation experiments demonstrated that neuronal expression of a spin RNAi showed a
statistically significant change in ST50 compared to the controls. However, I need to determine
that the expression of the RNAi in the neurons is the only factor contributing to that significant
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ethanol sedation phenotype. In order to determine this a series experiments were done to
verify that the RNAi expression was the only factor influencing ethanol sedation.
Results
Immunohistochemistry to verify knockdown of spin in neurons
Brains of flies expressing the spin RNAi in neurons were dissected and stained for spin
(anti-spin) and neurons (anti-elav) using immunohistochemistry. Images were taken at 10x
magnification to see if we were able to determine knockdown at the lowest magnification
using confocal laser microscopy and image processing. Macroscopically, it appeared to show
knockdown of spin compared to the control brains (figure 8A-C). However, formal image
analysis showed no statistically significant change in spin expression (figure 8D).
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Figure 9: Whole brain spin expression and validation of spin RNAi transgene. A-C: representative
(10x) confocal images of whole mount brains immunolabeled with anti-elav (neurons; green) and
anti-spin (red). Macroscopically, in control flies ( A, elav/+ and B, spin RNAi/+) expression of spin
seems prominent (arrowheads) compared to neuronal knockdown ( C ). D) quantification of spin and
neuron immunolabeling. Pixel intentsity derived from z-stack of all images of whole brains showed
no statistically significant in expression compared to the control brains (Bonferroni Multiple
comparisons (BMC); p>0.9999 for all genotypes; n=3). The quantification provided in 5D is derived
from numerous images representing all portions of the 3 brains per genotype.
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Discussion
spin is a Mef2-bound gene that is a candidate in ethanol sedation. Confocal laser
microscopy and image analysis revealed no significant change in expression compared to
controls, even though macroscopically it looks like there is a change (figure 8). Further imaging
and analysis need to be completed to determine if the RNAi is knocking down its intended
target of spin or off target genes. Further imaging of the co-localization of spin and neurons also
needs to be evaluated since the literature suggests spin is primarily located in glial cells with
some studies showing spin expression at the neuromuscular junctions (NMJs) (Sweeney and
Davis, 2002; Yuva-Aydemir et al., 2011).
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Chapter 4- Proposed analysis of spin and Mef2 in ethanol sedation
A. Introduction
Previous results suggest that spin (spinster), a Mef2 bound gene, may influence ethanol
sedation in Drosophila melanogaster. A gene screen using ethanol sedation of Mef2-bound
genes showed that neuronal expression of an RNAi targeting spin showed a higher ST50,
suggesting the flies are more resistant to ethanol. This led us to hypothesize that this gene
may be an ethanol sedation candidate gene in flies. Further genetic manipulations of spin
were done to further investigate spin’s role in ethanol sedation. We used transposable
elements inserted into the spin gene to determine if that also changed ethanol sedation.
The transposons were backcrossed so they had the same genetic background and PCR
experiments were done to determine the precise location of the transposons within the
gene. The backcrossed spin transposon-containing flies were tested against control flies in
ethanol sedation. Out of the three different transposons tested, two gave a statistically
significant change in ethanol sedation (K09905 and EY10097). The third transposon tested
(EY08566) showed no change in ethanol sedation suggesting that maybe the transposon
insertion does not affect gene expression enough to give a change.
The genetic analyses I performed strongly suggests that spin influences ethanol sedation
in flies. Several key questions that if answered would inform the validity of this possibility,
however, remain unanswered. Here I describe a series of experiments to answer these
questions to help determine if spin has a bona fide role in ethanol sedation in Drosophila
melanogaster.
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B. Is spin expressed in neurons and does the neuronal expression of spin RNAi or the
transposon insertions affect spin gene expression?
Rationale
1. My major experimental hypothesis is that Mef2-regulated expression of genes in
neurons is required for normal ethanol sedation. A fundamental prediction of this
hypothesis is that spin (as a candidate Mef2-regulated gene) should be expressed in
neurons. Additionally, determining the expression pattern of spin in the brain could
support more refined hypotheses regarding specific brain regions, types of neurons,
neurotransmitter systems, or possibly cellular compartments of neurons that might be
important for the role of spin in ethanol sedation.
2. My studies show that expression of a spin RNAi transgene in neurons makes flies
resistant to ethanol sedation, suggesting that spin functions within neurons and that the
RNAi impacts ethanol sedation by knocking-down this expression. RNAi transgenes can
have off-target effects (i.e. alter expression of other, unknown genes), making it
essential to explicitly determine whether the spin RNAi in neurons is in fact knockingdown spin expression. My confocal imaging and image processing at 10x magnification
showed no significant change in spin expression (figure 8D). However, this lowresolution analysis may not have revealed subtle changes in gene expression or changes
in expression in a small subset of neurons. In order to further study these hypotheses,
an approach would be to image and process at a higher magnification. Demonstrating
the knockdown of spin in neurons using the spin RNAi will help link the gene to ethanol
sedation and establish its function in neurons.
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3. My experiments show that flies harboring either of two independent transposon
insertions in or near spin have decreased ethanol sedation sensitivity. Based on the
locations of the spin transposons and the ethanol sedation changes seen, it can be
predicted that these insertions changed the expression of spin. The expression can
decrease, increase, or stay the same. Determining the expression of spin in flies with the
transposon insertions will help link spin to ethanol sedation and provide additional
context for interpreting the results of spin expression studies in RNAi flies above. It is
therefore critically important to look at the expression of spin in flies with transposons
that impact ethanol sedation.
Hypotheses and/or predictions to be tested
1. spin is expressed in neurons.
2. The spin RNAi ought to show a statistically significant change in spin expression in the
flies that have the neuronal expression of the spin RNAi compared to the controls when
viewed at a higher magnification.
3. The transposon insertions in the spin gene should show a change in expression
compared to the control flies since there was a change in ethanol sedation.
Approach
For 1, 2, and 3, immunohistochemistry, confocal laser microscopy (confocal imaging) and
image processing will be used to measure gene expression of spin.
1. Flies of the following genotypes: elav control (neurons), RNAi control, and neuronal
expression of spin RNAi will be dissected manually and fixed in paraformaldehyde (n=6 for
each genotype). Flies will be stained for spin (anti-spin antibody) and neurons (anti-elav;
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stains the elav protein, located in cell bodies). The brains of each genotype will be imaged
using laser confocal microscopy and those images will be processed using image software in
the VCU microscopy core to determine localization of the spin protein in relation to the
neurons. This will be done at 10x and 40x magnification.
2. Flies of the following genotypes: elav control (neurons), spin RNAi control, and neuronal
expression of spin RNAi will be dissected manually and fixed in paraformaldehyde (n=6 for
each genotype). Flies will be stained for spin (anti-spin antibody) and neurons (anti-elav;
stains the elav protein, located in cell bodies). Since there was no change in expression at
10x magnification, laser confocal microscopy will be done at a higher magnification (40x).
Those images will be processed using image software in the VCU microscopy core to
determine if there is a change in gene expression compared to genetic controls (elav and
RNAi control).
3. Flies containing the transposon (EY10097 and K00905), and wild type flies (w[A]) will be
manually dissected and fixed in paraformaldehyde (n=6 for each genotype) The brains will
be stained for the spin protein (anti-spin antibody). These brains will be images using laser
confocal microscopy and processed using image processing software in the VCU microscopy
core.
Anticipated results
1. If we see that the spin protein has significant co-localization (overlapping) with elav
(located in the cell body of the neuron), that will mean spin is expressed in neurons and
most likely localized in the cell bodies of neurons. If we see that the spin protein has no
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significant overlap with elav, then the spin protein may be located in another portion of
neurons, subset of neurons, or in a non-neuronal cell type.
2. If we see a significant decrease in pixel/particle intensity in flies expressing spin RNAi
compared to controls, then that will demonstrate that the RNAi is knocking down spin in
the neurons. This will strongly support the possibility that the ethanol sedation
phenotype seen in chapter 3 (figures 1 and 2) is the result of the spin knockdown. If we
see no significant change in pixel/particle intensity compared to controls when the 40x
magnification images are being processed, that will mean the spin RNAi is not
detectably knocking down the spin gene.
3. If we see a significant change in pixel/particle intensity in flies with the transposons
compared to controls, that will demonstrate the transposon insertion is changing spin
expression. This would strongly support the possibility that the transposon insertion is
affecting the ethanol sedation phenotype seen in chapter 3 (figure 8) via a change in
spin expression. If we see no significant change in pixel intensity compared to controls
when the images are being processed, that will mean the transposon insertion is not
changing gene expression.
Potential pitfalls
1. Unable to determine spin location in neuronal cell bodies marked with anti-elav. If this
happens I will stain the brains for spin and a new antibody targeting a different part of
the neuron or other cell types. However, I will focus on neurons given the neuronal spin
RNAi data in figure 8 from chapter 3.
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2. There is no significant change in spin expression compared to the control genotypes at
40x magnification. I will measure co-localization between elav protein and spin protein
in all control genotypes and neuronal RNAi expression. If there is a change in colocalization compared to the controls, it may suggest a functional change in spin
expression due to RNAI or transposon insertions.
3. spin RNAi knocks down spin expression as expected, but spin expression is increased in
one or more transposon lines. This result would suggest that either decreased or
increased expression of spin in neurons could lead to blunted ethanol sedation
sensitivity. This result would be consistent with a model in which spin is required for the
normal function of specific neurons involved in ethanol sedation, and that decreased or
increased expression of spin disrupts the function of those neurons, resulting in blunted
ethanol sedation.
C. Does neuronal expression of spin RNAi or do transposon insertions in spin affect internal
ethanol?
Rationale
It is possible that the primary impact of spin is to regulate how neurons respond to
alcohol. Alternatively, it is possible that the primary impact of spin is on the uptake/metabolism
of alcohol, and the altered uptake/metabolism of alcohol in flies with genetic manipulation of
spin changes internal alcohol levels which has a secondary effect of altering ST50 values. These
are two fundamentally different possible mechanisms for the role of spin, necessitating an
explicit series of experiments to address them.
Hypotheses and/or predictions
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The genetic manipulation of the spin gene in the flies will have one of two phenotypes:
1) Flies with genetic manipulation of the spin gene will have no significant change in
internal ethanol suggesting the genetic manipulation has no effect on how the fly
takes up or metabolizes the drug.
2) The genetic manipulation of spin will alter (presumably decrease) internal alcohol
levels in flies.
Approach
We will measure the internal ethanol of flies with the genetic manipulation of neuronal
expression of spin RNAi and transposon insertions in spin compared to control flies.
a. Neuronal expression of spin RNAi: These flies will be tested against two genetic controls,
elav control (n=11 vials) and spin RNAi (n=11 vials)
b. Transposon insertion in spin gene: Flies with the spin transposon insertion (n=11) will be
tested against wild type flies (w[A], n=11)
Internal ethanol will be tested at half ST50, and at ST50 for both a. and b. After exposure to
ethanol for those two-time points flies will be homogenized. The fly’s internal ethanol will be
extracted with water and then measured using gas chromatography equipped with a flame
ionization detector. The ethanol concentration will then be quantified by internal standard
methods.
Anticipated results
If we see there is no change in internal ethanol in spin manipulated flies compared to
control flies, that will suggest the genetic manipulation (neuronal expression of spin RNAi and
transposon insertions) are not affecting the fly’s ability to metabolize ethanol. This result would
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indicate that the genetic manipulation of spins in neurons (RNAi expression) or the transposon
is affecting the change in ethanol sedation seen previously by altering how neurons respond to
ethanol (i.e. having a pharmacodynamic effect).
Alternatively, if manipulation of spin changes internal ethanol, then that will suggest
that the genetic manipulations to spin is influencing the uptake/metabolism of ethanol and the
resulting altered internal ethanol concentration in the flies is affecting the change in ST50. This
result would be consistent with the change in ST50 seen in flies with altered spin being
secondary to the change in internal ethanol, raising the possibility that spin influences the
uptake or metabolism of alcohol.
D. Is there a genetic interaction between spin and Mef2?
Rationale
Mef2 influences ethanol sedation and spin is a gene bound by Mef2. spin appears to also
influence ethanol sedation. These findings support a model in which Mef2 is a transcriptional
activator of spin and Mef2 is therefore genetically upstream of spin for ethanol sedation. The
goal of this section is to begin to formally address this model through an integrative moleculargenetic-behavioral strategy.
Hypotheses and/or predictions to be tested
Since (i) Mef2 binds spin and (ii) decreased expression of either Mef2 or spin (presumed
from my RNAi studies) causes ethanol sedation resistance, we postulate that Mef2 is a positive
regulator or spin expression. Consequently, we predict that decreased expression of Mef2
should cause decreases expression of spin, and that increased expression of spin would be
epistatic to decreases expression of Mef2 for ethanol sedation. The studies described here will
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address these two foundational predictions and will therefore aid our understanding of Mef2,
spin, and the functional interactions between them in ethanol sedation.
Approach
Mef2 will be knocked down in the fly using RNAi. Those flies will be manually dissected
and fixed in paraformaldehyde (n=6 for each genotype). Brains will be stained for Mef2 (antiMef2) and the spin protein (anti-spin). Fly brains will be images using confocal laser microscopy
and image processing. Genotypes that will be tested are: Mef2 RNAi knockdown fly, GAL4
control fly, and RNAi control fly (n=6 for each genotype). Once we can determine the
expression pattern of Mef2 and spin we will be able to study the molecular mechanism of spin
and Mef2 in ethanol sedation.
Ethanol sedation will be used to study the behavioral genetics of Mef2 and spin. Four
genotypes will be tested: GAL4 control, Mef2 knockdown, overexpressed spin flies, and Mef2
knockdown with overexpressed spin flies (n=8 for each genotype).
Anticipated results
Mef2 expression should decrease in flies expressing Mef2 RNAi as the Grotewiel lab has
previously demonstrated. If spin is likewise decreasing in the flies, the results will indicate that
Mef2 is an activator of spin. Since knockdown of Mef2 and knockdown of spin both show
resistance to ethanol sedation, overexpressing spin in Mef2 knockdown flies will show a
decrease in ethanol sedation resistance.
Potential pitfalls
If image processing of the brains shows no significant change in spin expression
compared to the controls, I will reimage the brains at a higher magnification to determine the
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expression of spin when Mef2 is knocked down in the flies. If I see a significant change in spin
expression at a higher magnification, then I will be able to conclude about the genetic
interactions between spin and Mef2. If ethanol sedation results show a different pattern then
described then those results will be inconclusive about the interactions between Mef2 and spin.
E. Discussion
If we are able to see a certain pattern of results from these experiments, for all genetic
manipulations to the spin gene, we will be able to determine if spin is a candidate gene in
ethanol sedation in flies. If we see changes in spin expression we can conclude that the RNAi
expression and the transposon insertion changes gene expression. If we also see no significant
change in internal ethanol and locomotor activity compared to controls, then we can conclude
that spin is a candidate in ethanol sedation in Drosophila melanogaster.
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Chapter 5-Discussion
Mef2 is the Drosophila melanogaster ortholog to human MEF2B. Human MEF2B was
found as gene that is related to SRE in a recent GWAS (Schmitt et al., 2019). When Mef2 is
knocked down using RNAi, there is a significant change in ethanol sedation. The flies with
knockdown of Mef2 show an increased tolerance to ethanol. Another study showed that Mef2
binds 342 genes (Sivachenko et al., 2013), which leads us to believe that genes bound by Mef2
may also play a role in ethanol sedation in Drosophila melanogaster.
A GSCAN was done on Mef2-bound genes to determine if any human ortholog genes are
related to AUD. It was determined that 15 human ortholog genes out of the 342 Drosophila
genes were associated to AUD. Using available RNAi reagents for the Drosophila genes, these
genes were tested using ethanol sedation to determine if the RNAi knockdown of any of the
genes influences ethanol sedation. Nine genes were tested using 36 RNAis and the elav-GAL4
driver under UAS expression. Only two genes showed significant change in ethanol sedation
when using a single RNAi to knockdown the gene. Spinster (spin) and Polyhomeotic-distal (ph-d)
RNAi showed significant change in ethanol sedation, showing an increase in ST50. Further
research on both spin and ph-d revealed that spin would become the primary candidate gene of
interest due to the availability of reagents.
The spin gene encodes a multipass transmembrane protein which is a late
endosome/lysosome membrane protein with the amino acid sequence of lysosomal sugar
carrier (Sweeney and Davis, 2002; Kim et al., 2017). In Drosophila, spin mutations were first
identified for their effect on courtship behavior, which is extremely strong mate refusal by
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females (Sakurai et al., 2010). Previous research demonstrated that loss of spin function also
causes synaptic overgrowth at the neuromuscular junction (NMJ)(Sweeney and Davis, 2002).
However, there has been no research into the effects of spin genetic manipulations on ethanol
response in Drosophila.
Transposons are DNA segments that are inserted into a gene to affect gene function or
expression (Bellen et al., 2011). These transposon insertion flies are made with different genetic
markers, signifying that they are present in the genome. P transposable elements are one of
the best studied DNA elements in eukaryotic DNA (Bellen et al., 2011). Using P transposable
elements inserted into the spin gene can be another genetic manipulation to help determine if
spin does influence ethanol sedation. Ethanol sedation of spin transposon insertion flies against
control flies (wA) revealed a significant change in ethanol sedation. However, in order to verify
that these genetic manipulations within spin do affect ethanol sedation in flies further tests
need to be conducted.
Further testing of neuronal expression of spin RNAi flies and P transposon insertion spin
mutant flies need to be conducted in order to determine if these manipulations are showing
knockdown of the gene. Using immunohistochemistry and confocal imaging, the location of
spin within neurons needs to be verified in order to help understand the molecular mechanism
causing the ethanol sedation change seen. Also using these techniques, we will verify that spin
RNAi is knocking down its intended target and not off target genes. We will also use
immunohistochemistry and confocal imaging to determine the molecular mechanism of spin P
element transposon insertions, since these insertions are known to disrupt gene function and
expression.
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Both the neuronal expression of spin RNAi and transposon insertions may disrupt
gene expression or function, and may influence other behavior or metabolic pathways of the
fly. In order to determine if these genetic manipulations influence non-ethanol related behavior
or metabolic pathways of the flies two assays will be performed. In order to determine if the
genetic manipulation affects metabolic pathways of the flies, internal ethanol of flies will be
measured. If there is a significant change in internal ethanol compared to genetic control flies,
then the ethanol sedation phenotype seen previously is the result of the genetic manipulation
influencing the fly’s ability to metabolize ethanol and not the fly’s behavior response to
ethanol.
By conducting the experiments described in chapter four on both genetic manipulations
to the spin gene, we can further understand the mechanisms of spin that influence ethanol
sedation in Drosophila melanogaster. It is known that the spin protein is located in late
endosomal/lysosomal compartments in nerve and muscle tissue and is required for synaptic
growth in cells (Sweeney and Davis, 2002). Mutations to spin have shown synaptic overgrowth
at the neuromuscular junction (NMJ) which consequently led impaired neurotransmission at
the NMJ. (Sweeney and Davis, 2002). Based on these observations, we can predict that
knockdown of spin using RNAi and/or transposon insertions may lead to similar results. If that is
the case, this could be the reason why there is a change in ethanol sedation using RNAi and
transposon insertions.
The model organism, Drosophila melanogaster, is a powerful tool to study the genetic
mechanisms of Alcohol Use Disorder (Singh and Heberlein, 2000). The behavioral responses to
ethanol exposure in flies is very similar to that in humans, with effects of locomotor, sedation,
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withdrawal symptoms, and tolerance (Grotewiel and Bettinger, 2015). With this in mind, it is
important to use Drosophila as a way to study genes that known to be associated with AUD
from association studies such as GWAS in humans. Once we can prove that the Drosophila
ortholog genes influence alcohol response in flies, we can translate that back to the human
level for further investigation.
By gathering genetic information influencing a fly’s response to alcohol, it can give us a
better understanding of the molecular mechanisms underlying AUD in humans. This can help
lead to better treatment options for patients currently battling with this disease. Currently,
most treatment plans for AUD involve 12-step groups, outpatient treatment by medical or
nonmedical healthcare providers, and under prescribed medications (Kranzler and Soyka,
2018). However, by understanding the genetic factors influencing AUD researchers can start to
develop gene targeted therapies to also aid in the treatment of Alcohol use disorder.
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Chapter 6-Appendices
A. GeneSwitch as an inducible gene expression system
1. Introduction
GeneSwitch (GS) is a GAL4 driver that is expressed in the presence of mifepristone
(RU486) steroid (Osterwalder et al., 2001; Nicholson et al., 2008). The steroid can be
administered in different ways; by either feeding the drug to the flies for an extended amount
of time, or by immersing the animals in a steroid solution (Nicholson et al., 2008). The drug will
bind to the GAL4 driver and change its conformation. The GAL4 driver is then in the correct
conformation to bind to the UAS (upstream activation sequence) and turn on gene expression
in a specific tissue (Nicholson et al., 2008) . The gene expression can be detected as early as
three to five hours after administrating the drug to the flies, with maximal expression being
observed 24-48 hours after administrating the drug (Osterwalder et al., 2001; Nicholson et al.,
2008).
While this inducible expression system can be used to activate gene expression, it can
also be used for expression of RNAi to knockdown gene function. GeneSwitch GAL4 has been
used to express genes or RNAis in a number of different tissues including muscle, neurons,
mushroom body-specific, eye-specific, glial cells, and tubulin (Nicholson et al., 2008). The goal
of this project is to identify a neuronal GeneSwitch GAL4 driver that works using our standard
RU486 feeding regime.
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2. Methods
GeneSwitch Feedings
All GeneSwitch adult female flies were fed 1mM of mifepristone (RU486). 1mM of
mifepristone was add to non-yeasted food vials as described in fly husbandry and stocks. All GS
flies were fed the drug for a total of six days. On day three, all GS flies were flipped onto fresh
non-yeasted vials with the mifepristone to prevent larval activity.
Locomotor activity
All Tetanus Toxin expressing GS flies were monitored on the drug for 6 days for decrease
in locomotor activity. The number of flies that were dead/paralyzed were recorded.
Beta-Galactosidase Assay
All LacZ expressing flies were homogenized with drill and pestle. LacZ was extracted
from flies using extraction buffer (1x PBS: 37 mM NaCl, 2.7 mM KCL, 8mM Na2HPO4, and 2mM
KH2PO4. 1x Protease inhibitor (protease inhibitor cocktail, Sigma-Aldrich, St. Louis, MO.)) 100 uL
of LacZ solution was added to 900 uL of 1mM Chlorophenol Red-β-D-galactopyranoside (CRPG)
(Sigma-Aldrich, St. Louis, MO) and read in a spectrophotometer (ultrospec 2000, pharmacia
Biotech, Piscataway, NJ.) at 562nm.
3. Results
Selecting GeneSwitch Drivers for screening
Six GeneSwitch lines were selected from the literature (Nicholson et al., 2008). These
geneswitch lines were all previously screened in third instar larvae and adult heads. The six lines
selected from this previous screen were all tissue specific to neurons (table 1). Two other lines
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(stock #81013 and #43642) were selected from based on previous research from other
collaborators.

stock

GS line

expression

P{w[+mW.hs]=Switch2}GSG3315-1, w[*]

ventral nerve
cord cells, a
few brain cells
& chordotonal
organs

59949

40333

y[1] w[*];
P{w[+mW.hs]=Switch2}betaTub56D[GSG5793]/CyO

40286

w[*]; P{w[+mW.hs]=Switch2}GSG3763

40283

w[*]; P{w[+mW.hs]=Switch2}GSG3630/TM6B,
Tb[1]

40294
43642

w[*]; P{w[+mW.hs]=Switch2}GSG4948
y[1] w[*]; P{w[+mC]=elav-Switch.O}GSG301

81013

w[1118]; P{w[+mC]=MB-Switch}3/TM6C, Sb[1]

40251

P{w[+mW.hs]=Switch2}GSG5970, w[*]

ventral nerve
cord, brain
and sensory
neurons

ventral nerve
cord and brain
neurons.
ventral nerve
cord, brain,
sensory and
neuromuscular
junction
neurons.
ventral nerve
cord, brain,
sensory and
neuromuscular
junction
neurons
Neurons
mushroom
body
expression.
subsets of
ventral nerve
cord, brain,
sensory and
neuromuscular
junction
neurons.
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Tetanus
toxin
expression
LacZ
(28837
induction stock)

tetanus
toxin
expression
(28838
stock)
source citation

no

no

no

BDSC

no

no

yes

BDSC

no

no

no

BDSC

no

no

no

BDSC

no
no

no
lethal

no
lethal

BDSC
BDSC

Nicholson
et al.,
2008,
Genetics
178(1):
215--234
Nicholson
et al.,
2008,
Genetics
178(1):
215--234
Nicholson
et al.,
2008,
Genetics
178(1):
215--234
Nicholson
et al.,
2008,
Genetics
178(1):
215--234
Nicholson
et al.,
2008,
Genetics
178(1):
215--234
NA

no

no

yes

BDSC

NA

BDSC

Nicholson
et al.,
2008,
Genetics
178(1):
215--234

no

no

yes

Table A. 1: Neuronal GeneSwitch lines tested with various reporter genes. All GeneSwitch lines
tested were found in the literature and are expressed in neurons.
Tubulin GeneSwitch expression of Mef2 RNAi in ethanol sedation
Tubulin GeneSwitch is a GS line that is expressed in all tissues. Previous research has
shown that Tubulin GS drives expression the reporter gene UAS-LacZ in a Beta-galactosidase
assay (figure 1). Since this GeneSwitch driver has shown successful inducible expression, I used
it to to express the Mef2 RNAi previously reported in the lab and test in ethanol sedation.
Tubulin induced knockdown in adult flies showed no significant change in ethanol sedation
compared to the controls (figure 1). This result could be because the tubulin GS line is
expressed in all tissues and that could be masking the effect of the Mef2 knockdown. These
results also give reason as to why a neuronal GeneSwitch driver is needed, an inducible
knockdown of Mef2 in a neuron-specific GeneSwitch driver could show different results.
B

Tubulin GS x UAS-LacZ
1.5

tubulin GS x UAS-lacz 0mM

0.5

40

0/
+

/+

0

55

50

15
G
S/
+;
v

30

minutes

55

20

20

tu
bu
lin

10

0mM RU486
40

tu
bu
lin
/+

-0.5

1mM RU486

v1

1.0
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tubulin GS x UAS-lacz 1mM
ST50 (min)

absorbance at 562nm

A

genotype

Figure A.1: Tubulin GeneSwitch used to induce gene expression. A) Tubulin GS used to
express UAS-LacZ reporter gene. There was significant expression of lacZ compared to
control flies. (Linear regression; p<0.0001; n=3) B) Tubulin GS used to knockdown Mef2 by
expressing Mef2 RNAi transgene (#stock v15550). There was no statistically significant
change in ethanol sedation (red) compared to controls. (2-way ANOVA; p=0.5744;
Bonferroni’s multiple comparisons BMC) p>0.999 for all genotypes; n=16).
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LacZ and Tetanus toxin as a reporter gene to test GeneSwitch driver
UAS-LacZ is a reporter gene that was used to screen all 8 of the GS lines (table 1). LacZ
expression was tested by measuring Beta-Galactosidase. No significant change was seen in the
induced lines compared to the uninduced lines (figure 2).
B
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Figure A.2: Neuronal GS expression of UAS-LacZ reporter gene. A-H expression of LacZ in neurons.
No significant change between flies that were exposed to the drug and those that were not being
exposed. A-C) simple linear regression. A) p=0.6498, B) p=0.5915, C) p=0.9330, D) p=0.4123, E)
p=0.9549, F) p=0.5915, G) p=0.1319, H) p=0.9456; n=3 for each genotype in all panels.
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These lines were tested again using two different UAS-Tetanus toxin lines (stock #28837
#28838). When tetanus toxin is expressed, it blocks neurotransmitter release, this will paralyze
and eventually kill the flies. Fly activity was measure over 6 days, recording the number of
paralyzed/dead flies each day. There was no significant change in flies being fed the drug
compared to the flies that did not get fed the drug (figure 3).
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Figure A.3: Neuronal GS expression UAS-Tetanus toxin (#28837). A-D No significant change between
flies that were exposed to the drug compared to those flies that were not. Simple linear regression B)
p=0.0162, C) p=0.0753, D) p=0.5514; n=3 for each genotype in each panel.
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The second tetanus toxin reporter gene (stock #28838) was then used to induce
expression of the tetanus toxin. This tetanus toxin revealed stronger expression when induced
with the neuronal GS driver (figure 4). Out of the eight lines tested for gene expression of the
tetanus toxin, three showed significant change compared to the uninduced flies (table 1; figure
5). This suggests that UAS-tetanus toxin (stock #28838) was a successful transgene that showed
gene expression in induced neuronal GS lines.
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4. Forward thinking
Introduction
Eight neuronal GeneSwitch lines were selected from the literature and from colleagues
(table 1). These Lines were tested to see if they activate a reporter gene (UAS-LacZ, UASTetanus Toxin) using our standard feeding regime. Results showed no significant change in LacZ
expression when flies were given the drug compared to those who did not get fed the drug
(figure 2). I then used a different reporter gene, UAS-Tetanus toxin (stock 28837) to test these
GS lines for gene expression. Once again, there was no change in expression compared to flies
who were not fed the drug (figure 3). I tried a different UAS-Tetanus toxin (stock 28838) to test
the lines and saw three GS lines that showed a significant change in expression (figure 4). These
results gave us promising data to determine if there is a neuronal GS driver that will express a
gene using our feeding regime.
Although we found three GS lines that showed expression of the UAS-Tetanus toxin
(figure 4), there is still more testing that needs to be done to determine if these neuronal GS
lines actually activate gene expression. We need to verify that the UAS-tetanus toxin (stock
28838) is a reporter gene that can test GS lines. We also need to verify that these GS lines do
activate gene expression by using a different reporter gene (UAS-GFP). Once we can verify that
these neuronal GS lines activate gene expression, these lines will be used to determine if
neuronal knockdown of Mef2 in adult flies has a change in ethanol sedation.
Rationale
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Identify a neuronal GeneSwitch driver that will activate gene expression. Then use that
neuronal GS driver to knockdown Mef2 expression in adult flies to determine if that changes
ethanol sedation compared to control flies.
Hypothesis
1) Identify a neuronal GeneSwitch driver that successfully activates gene expression of a
reporter gene.
2) Once a neuronal GS driver has been properly screened, determine if there is a change in
ethanol sedation when Mef2 is knocked down in adults.
Approach
Since we have screened all eight neuronal GS drivers, and found three lines that gave
promising results, the next steps are going to be further testing of these lines to determine if
they are GS candidates.
1) The three GS lines that showed tetanus toxin expression will be crossed to UAS-tetanus
toxin (stock 28838), given the food for six days, and monitoring the fly’s activity over the six
days they are exposed to the drug. Flies that are being fed the drug will be compared to flies
that are not being exposed to the drug. This will be done to verify that the UAS-tetanus
toxin is the right reporter gene to measure gene expression of these neuronal GS lines.
Once this experiment is done, these GS lines will be tested again with a different reporter
gene to confirm that the lines turn on gene expression when exposed to mifepristone.
Neuronal GS flies will be crossed to UAS-GFP and fed the drug for six days. These flies will be
compared to flies that are not fed the drug, and both sets of flies will have dissections of the
brains. The brains will be imaged using confocal laser microscopy, those images will be
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processed to determine if there is significant expression of GFP in flies fed the drug
compared to flies not fed the drug.
2) Once a neuronal GS has been properly screened and identified, the GS driver will be used to
knockdown Mef2 in adult fly neurons and tested with ethanol sedation. These flies will be
tested against the neuronal GS control and the Mef2 RNAi control. All three genotypes will
have flies that exposed to the drug and flies that are not exposed to the flies.
Anticipated results
1) If we see that at least one of the three GS drivers show significant expression of UAStetanus toxin and UAS-GFP, then that will confirm that those GS drivers do activate gene
expression.
2) If we see that the neuronal knockdown of Mef2 in adult flies has a significant change in
ethanol sedation, then that will mean the knockdown of Mef2 in adults also can impact the
fly’s response to ethanol.
Potential pitfalls
If we are unable to find a GeneSwitch driver that induces expression of a reporter gene
then that can mean that the flies are not being properly exposed to the drug. In this case, we
will change the feeding regime of the drug to the flies. If we find that the flies are being
exposed to the drugs but they are not inducing gene expression then the next thing to do is to
look for other neuronal GS drivers and re-test with the previously used reporter genes: UASLacz, UAS-tetanus toxin, and UAS-GFP.
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5. Discussion
GeneSwitch (GS) is a GALD4 driver that will express a gene or RNAi in the presence of
mifepristone (RU486) (Osterwalder et al., 2001). We were interested in finding a GS driver that
works in neurons because previous ethanol sedation experiments using Tubulin GS to
knockdown Mef2 showed no significant change in ethanol sedation (figure 12). Eight GS lines
were tested using multiple reporter genes (UAS-LacZ, UAS-tetanus toxin). It was clear that
measuring fly activity by expressing tetanus toxin was the best method to test these
GeneSwitch lines. Further studies will need to be done verify that the three GS lines that
showed expression of the tetanus toxin (figure 15) is consistent. From there, using the neuronal
GS lines to knockdown Mef2 in adult flies to see if there is a change in ethanol sedation will be
done.
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B. Protocols
1. Basic Fly Handling and Husbandry
A. Standard Fly Lab Lingo:
1. Stock or strain: a culture of flies with a particular genotype. Balanced stocks have a special
chromosome called a balancer that is marked with a dominant phenotype and suppresses
recombination on the corresponding sister chromosome. Balanced stocks are often weak (i.e.
grow poorly).
2. Seeding: putting adult flies into a new bottle or vial. Also called ‘setting-up’.
3. Transfer: moving flies without anesthesia from one vial or bottle to another. One-to-one
transfer means moving flies from one bottle/vial to one new bottle/vial. Two-to-one transfer
means moving flies from 2 vials/bottles to 1 new vial/bottle. Also called ‘flipping’.
4. Clearing: removing all of the adults from a bottle or vial. Can be done with or without
anesthesia.
5. Anesthesia: CO2 used to temporarily immobilize flies.
6. Brood: refers to the number of times a set of adults has been used to seed bottles. Using flies
for 2 broods is common, with 3 broods being possible in some cases.
7. white plus (w+): indicates eye color. white minus (w-) flies have white eyes. w+ flies have eyes
that can vary from light peach to deep red.
8. Food: All of our fly food currently has antibiotics on it (ampicillin, tetracycline and
chloramphenicol; i.e. ATC). Yeasted (Y) food vials and bottles have live yeast on added. Yeasted
food should be used for seeding new vials and bottles for growing flies. Non-yeasted (NY) food
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has no yeast on it and should be used to house flies prior to behavioral studies and for storing
virgin females and males prior to setting-up crosses.
B. Standard Fly Husbandry
1. Remove necessary number of yeasted bottles or vials from the cold room. Use bottles to
grow lots of flies for behavioral or other large experiments. Use vials for smaller numbers of
flies in limited scale crosses or other small-scale experiments.
2. Before putting in new flies, bottles and vials must be dried 2 hours to overnight in the
environmental chamber so that all condensation on the walls evaporates. The food will pull
away from the wall of the bottle or vial if they are over-dried. It is poor practice to use overdried food.
3. Turn on the CO2. Clean microscope, CO2 pad and counter with ethanol. Clean before starting,
between each genotype and after you are finished. Be sure the CO2 is on before putting ethanol
on the pad.
4. Open CO2 to pipette, invert bottle or vial, insert pipette along cotton plug and tap bottle/vial
gently. Flies will become anesthetized quickly and should fall onto the plug and/or the neck of
the bottle/vial.
5. Click off CO2 to pipette, remove CO2 pipette from vial/bottle. Hold inverted bottle/vial over
CO2 pad. Remove plug and gently shake/tap flies onto pad into a pile. Return plug to bottle/vial
and set aside.
6. Use brush or spatula to place anesthetized flies in a row and sort flies according to needs.
Short CO2 times are important. For collecting flies that will be used in behavioral studies, goals
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are (1) all genotypes experience the same CO2 exposure and (2) all flies are anesthetized for less
than 5 min.
7. Set-up new bottles/vials by putting sorted flies from step 6 into dried bottles/vials.
Anesthetized flies should be kept on the wall of the bottle/vial. If they fall into the food, many
of them will stick there and die. Robust strains such as w[A] will do well with 10 females (♀,
see below) per bottle or 3 females per vial. It is good practice to include a comparable number
of males (♂, see below). Weaker stocks will need more females, up to as many as 50 per bottle
and 15 per vial. When working with a stock that is new to you it is good practice to seed bottles
or vials with a range of females (10-25/bottle for example) and then use an optimum number
thereafter based on how the various bottles/vials grow.
8. Insert cotton plug, invert new bottle/vial and tap anesthetized flies onto the plug. Lay the
bottle/vial on its side, label with genotype and date. First broods (i.e. bottles or vials in which
the flies are new parents) are marked with a single slash.
9. Wait for flies to regain locomotor activity. Turn bottles/vials upright and place in
environmental chamber to grow.
10. Beginning at around 4 days after seeding, check bottles/vials daily for larval activity (darkish
band on top of food). When larval activity is obvious, either discard the adults or—if a second
brood is needed—transfer adults to new bottles/vials (dried appropriately). Label second brood
with genotype, date and two slashes.
11. Beginning at around 4 days after seeding the second brood, check bottles/vials daily for
larval activity. Discard adults when larval activity is obvious. If necessary, a third brood is
possible in some cases.
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12. You should expect to see obvious larval activity 4 to 7 days after seeding and obvious pupae
5-10 days after seeding. New adults should begin emerging ~10 days after seeding. Some
strains, especially balanced strains, can take up to 4 additional days to generate adults.
Perfectly seeded bottle/vials will have robust larval activity followed by large numbers of pupae
that populate the bottom three-fourths of the wall of the vial or bottle. Pupae will not typically
be in the food or on the plug in these bottles. Large numbers of healthy adults suitable for
experiments will emerge from perfectly seeded bottles/vials.
13. Common Problems: If your bottles/vials are too dry or wet (as described below), the
resulting adults should not be used for behavioral, stress or gene expression studies. The
resulting adults are fine genotype-wise and reproduction-wise, though, and can be used to setup new bottles/vials as necessary.
a. Food too dry after 4-7 days of new adults in bottle/vial: The food should not be so dry
that it detaches from the wall of the bottle of vial and the pupae are in the food. In cases like
this, the food was either over-dried, there were not enough females placed in the bottle/vial, or
possibly both. If this occurs across several strains that have grown well in the past, it is likely
due to over-drying. If it occurs with a subset of strains, it is more likely due to insufficient
numbers of females being used for those specific strains. The appropriate fixes are to decrease
drying time, add more females next time, or both.
When you transfer flies from the first to second brood or when clearing the second brood,
note the quality of the culture and food. If the food in some bottle/vials is detached from the
wall after 7 days, go ahead and transfer/clear the adults and then add ddH2O (NOT ETHANOL!)
to the bottle/vial until the gap between the food and the wall is filled. In many cases this will
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help the larvae quite a lot and you still might get a decent yield of adults, although they might
be delayed a few days due to lack of water.
b. Food too wet after 4-7 days of new adults in bottle/vial: The food should not be so
wet that it runs down the wall of the bottle/vial when it is inverted and the pupae are on the
plug. If this happens, the food was not dried sufficiently before adults were added, too many
adults were added, or possibly both. If this occurs across several strains that have not had this
problem in the past, it is likely due to under-drying the food. If it occurs with only a subset of
strains, it is more likely due to too many females being added in those specific strains. The fixes
are to increase the drying time for bottles/vials, decrease the number of females used, or both.
If you notice that your bottles are too wet when transferring from the first to second
brood or when clearing the second brood, you can put a folded Kim wipe in the bottle/vial so
that it touches both the food and the plug. This will not result in a miraculous drying of the
bottle/vial, but it can convert a bottle/vial that is far too wet into one that can be managed with
some care.
C. The Basics of Setting-Up Crosses
1. You will need males (♂, mated or unmated) and virgin females (♀ with a ‘v’ on top) for your
crosses. Grow bottles or vials as above for strains required to generate males and virgin
females. For planning purposes, you can comfortably collect 50-100 males and/or 25-50 virgin
females from a robust bottle. Likewise, you can probably count on collecting 15-20 males and 510 virgin females from each well-seeded vial.
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2. Around day 10 after seeding, begin to collect virgin females, identified by their light body
pigmentation and female genitalia (see below). Typically, one collects virgin females first thing
in the morning, again around noon, and again last thing before leaving for the day.
3. Keep virgin females in non-yeasted vials with no more than 25 females/vial. Label each vial
with genotype, date and number of virgins collected. Keep collected virgins in environmental
chamber until ready to use. One will often collect virgin females over several days until a
sufficient number of virgin females has been collected. Also, it is convenient to store virgin
females in upside-down vials.
4. When sufficient numbers of virgin females have been collected (~10% more than you plan to
use) or when it is obvious that you will be able to collect all the virgin females you will need,
collect all males into non-yeasted vials needed for your crosses. Males are identified by their
male genitalia (see below).
5. Set-out yeasted bottles or vials to warm and dry as described above. On the day of the cross,
check all virgin female vials for larvae using the microscope. Any vials with larvae MUST be
discarded because at least one of the females has mated. Use only virgin females from vials
with no larvae.
6. To set-up a cross, anesthetize the males and check them, anesthetize the virgin females on
the same plate and check them, and put appropriate numbers of males and females into
yeasted bottles/vials as described in steps B7-B9 above. Handle them thereafter as described in
B10-B12 above.
7. Make sure that you know what progeny to expect from your crosses before you set them up.
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2. Ethanol Sedation Assay
A. Day before assay
1. Collect flies (reared for behavioral assays) in groups of 11 (single sex) under brief CO2 (~5 min)
following standard procedures for behavioral assays. Collect only those flies that look healthy, are
relatively the same size, have normal wings, and appear dry. Flies should be transferred from the CO2
plate into an Eppendorf tube using a funnel and then dumped from the Eppendorf tube into a nonyeasted vial.
2. Allow flies to recover overnight in upside-down non-yeasted food vials in the environmental chamber.
It is possible to test a maximum of 24 vials of flies in a single experiment.
3. Dilute ethanol solution as necessary (85% is our standard concentration). ~250 ml of ethanol solution
can be stored in a sealed 500ml bottle or other sealed container for a week without a problem. Make
ethanol fresh weekly. Diluted ethanol is exothermic and should be stored overnight at room
temperature before use.
B. Day of assay
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1. For each vial of flies to be tested, you will need (a) a clean, empty food vial; i.e. testing vial, (b) a new
Flug, (c) a silicone #4 plug and (d) 1.0 ml of ethanol solution (85% ethanol is our standard
concentration).
2. Turn on humidifier and allow relative humidity in testing room to rise to 55-65%. Temperature should
be 20-23°C. Record humidity and temperature on test log.
3. Have someone else in the lab assign a unique code to each group of vials for each genotype and—
IMPORTANTLY—record the code for later. Place coded vials with flies in testing room to acclimate.
4. Label empty testing vials to match codes on fly vials from B.3.
5. Construct a testing log by entering the code for each vial into the Test Log E or Test Log EE sheet
within the Excel Sedation file SA E EE 6 min SIGMOIDAL 2015.10.05. Use a random or cycling order. Add
other pertinent information (% ethanol, sex, etc.) to the Test Log worksheet and print for use during
testing.
6. Using the Test Log as a guide, arrange coded food vials with flies and empty testing vials into matching
arrays with 4 vials in each row. The maximum possible number of vials that can be tested in a single
experiment is 24 vials (i.e. 6 rows of 4 vials each).
7. Transfer flies from food vials into matched/labeled testing vials one at a time and immediately insert
Flugs into testing vials until Flugs are a uniform distance below the vial tops. Use the Fluginator to push
Flugs down into vials.
8. Time 0 assessment: Grasp each vial individually with thumb and forefinger, tap gently on the table
three times to knock flies to the bottom of the vial, wait 30 seconds and then count the number of flies
that are immobile. Typically, this is 0 or 1 at time 0. Record the number of immobile flies for each vial at
time 0 in the printed Testing Log.
9. Hereafter, each row of four vials will be handled as a set at staggered one-min intervals.
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Start timer counting up at time 0 and immediately begin adding 1 ml of ethanol to the Flug in the vials
for the first row/set of 4 vials. Add ethanol to the vials at 5 second intervals in the order they will be
tested. Add ethanol to the Flugs in a circular motion so that all ethanol is absorbed as uniformly as
possible. When ethanol has been added to all four testing vials in the set, insert a silicone #4 plug in
each vial to seal it.
At times 1, 2, 3, 4 and 5 min on the timer, add 1 ml of ethanol to the second, third, fourth and fifth sets
of 4 vials, respectively. Continue inserting #4 plugs after adding ethanol to each set of 4 vials.
10. At time 6 min, test the first set of 4 vials by grasping the first vial with thumb and forefinger and then
tapping gently on the table three times to knock flies to the bottom of the vial. Tap the other 3 vials in
the set the same way at 5 second intervals. 30 seconds after tapping the first vial, count and record the
total number of flies that are sedated. Count and record the number of sedated flies in the other 3 vials
at 5 second intervals. Flies are scored as sedated if they do not appear to have productive locomotion.
The specific schedule is:
Vial

Tap

Assess

1

6 min 0 s

6 min 30 s

2

6 min 5 s

6 min 35 s

3

6 min 10 s

6 min 40 s

4

6 min 15 s

6 min 45 s

At times 7, 8, 9, 10 and 11 min, test the second, third, fourth, fifth and sixth sets of vials, respectively, as
done for the first set.
11. At time 12 min, test the first set of 4 vials again as described in B10 and continue testing the second,
third, fourth, fifth and sixth sets of vials at 13, 14, 15, 16 and 17 min, respectively.
Continue testing flies as described in B10 and B11 until all flies are sedated (typically 60-90 min).
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12. Record the total number of flies in each vial.
13. Clean-up is (a) turn off humidifier, (b) remove #4 plugs for washing and reuse, (c) discard
Flugs/vials/flies, (d) remove any trash from and straighten up testing room and (e) turn off light in
testing room.
14. Enter the total number of flies in each vial and the number of flies sedated at each time point in the
Test Log within the Excel worksheet. Percent Active flies will be automatically calculated and graphed
below the Test Log. Press ‘Ctrl + s’ to calculate ST50s for each vial and sort the data by group in the
Sorted Data worksheet.
15. Note any flagged data in Sorted Data worksheet. Consider excluding data that looks qualitatively
poor.
M Grotewiel, R Schmitt, K Lee: 7/2014, 3/2015, 7/2016

3. Fixation, Staining, Mounting, Imaging and Analysis Protocol for Whole Adult Drosophila Brains
Dissection: Day 1
1. Anesthetize flies and place adults of the appropriate age, genotype and gender into a three-well dish
on ice
2.

Fill another three-well dish with PBT and place it under the dissecting microscope
3. Place a 0.5mL snap cap tube containing 500µL of freshly prepared 4% paraformaldehyde on ice

4.
With gentle, sharp forceps, remove the brain from the head cuticle in the PBT solution. Place it
into the 4% paraformaldehyde on ice
•
•
•

•

Sharpen forceps with sharpening stone prior to dissection
Use clean forceps during dissection – have wet Kim wipes ready to wipe fly parts onto
The best way to access the brain = dunk flies into PBT belly up. Use second forcep to remove the
proboscis, which will leave a large hole in the flies’ head. Grab ahold to opposite sides of the
hole with both forceps, and slowly pull the forceps away from each other to remove the cuticle.
• Demonstrated here: https://www.youtube.com/watch?v=j4rVa7JCzdg&t=5s
Things to remember:
• The retinas and eye pigment auto-fluoresce. Make sure they are fully removed!
• Too much connective tissue left on the brains (white stringy stuff) will cause the brains
to float, which makes them harder to stain. Remove as much as possible
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5.

Repeat for the remaining flies. Place up to 10 brains in a tube

Staining:
*** Wear black gloves. Always check pipet tips to ensure brains were not sucked up with solution. All
excess solution (unless noted otherwise) can be discarded into a small beaker and washed down the sink
***
*** Make sure all primary and secondary antibodies have been optimized for concentration. Directions
on how to do this are in the Notes section below***
Day 1 (~3 hours)
1. Place the 0.5mL tube containing brains in 4% paraformaldehyde onto a nutator. Allow the brains to
fix for 20 min at room temperature
2.
Remove the tube from the nutator and place it into a tube rack at room temperature. Allow the
brains to settle to the bottom of the tube. Use a P-200 pipet to remove the paraformaldehyde. Dispose
appropriately under fume hood.
3. Add 0.5mL PBT to the tube. Close and invert the tube. Allow the brains to settle to the bottom.
Remove the PBT. Repeat once more (=2 quick washes at room temp)
4.
Add 0.5mL PBT to the tube. Place on nutator to wash for 20 min. Repeat two more times (=3
20min washes at room temp)
5.
Remove the PBT from the brains and add 0.5mL block solution (5% NGS). Place brains on nutator
to block for (at least) 30 min at room temp.
• A little bit longer than 30 min is okay
6.
Remove block solution from the brains. Add the primary antibody solution at the predetermined concentration. Place on nutator at 4°C for 2 nights (approx. 36-48 hours).
** can be increased to 1 week if antibody penetration isn’t good
Day 3 (~1.5 hours)
7.
Remove primary antibody and store it at 4°C. The antibody can be reused roughly three + more
times.
• Always record the dates and number of times used!
• These antibodies could have bacteria in it ☹ beware
8.
Add 0.5mL PBT to the tube. Close and invert the tube. Allow the brains to settle to the bottom.
Remove the PBT. Repeat once more (=2 quick washes at room temp)
9.
Add 0.5mL PBT to the tube. Place on nutator to wash for 20 min. Repeat two more times (=3
20min washes at room temp)
10.
Remove PBT. Add secondary antibody at the pre-determined concentration. Place on nutator at
4°C for 2 nights (approximately 36-48 hours).
** can be increased to 1 week if secondary antibody penetration isn’t good
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(this should not be an issue with AlexaFlours – if troubleshooting penetration issues with an Alexa
secondary antibody, start with increasing the primary antibody exposure time)
Day 5 (~2.5 hours)
11.
Remove the secondary antibody and discard
12. Add 0.5mL PBT to the tube. Close and invert the tube. Allow the brains to settle to the bottom.
Remove the PBT. Repeat once more (=2 quick washes at room temp)
13.
Add 0.5mL PBT to the tube. Place on nutator to wash for 20 min. Repeat two more times (=3
20min washes at room temp)
** DAPI can be added to one of the 20 min washes to stain nuclei
14.
Remove PBT and add 200µL SlowFade. Allow brains to settle in SlowFade at 4°C. This normally
takes 1 hour
** Do not leave brains in SlowFade for more than 24 hours
Mount brains:
1. Label slide with pencil
2. Use a P-200 pipet tip to transfer the brains in SlowFade from the tube onto a mounting slide.
Only transfer a little SlowFade at a time (100uL or under) - avoid adding excess SlowFade. Excess
SlowFade can be removed with a kimwipe.
3.
•
•

Using forceps, carefully align the brains for ease of imaging.
Place flat against the bottom of the slide. Arrange in a line
No great videos for this, but you’ll get the idea through these two videos…
• https://www.youtube.com/watch?v=ga9wre91T7M
•
https://www.youtube.com/watch?v=yHoN1PzsTaA (first four min only)

4.
Arrange two broken no. 1 coverslips on the microscope slide on opposing sides of the mounted
brains in SlowFade (aka bridge). Do not let the coverslips touch the SlowFade. Gently place a no. 1
coverslip on top of the bridge to cover the brains
• This technique prevents the brains from becoming too compressed under the top coverslip
5.
Slowly pipet SlowFade under the coverslip on the bridge (surface tension will allow the
SlowFade to go under the coverslip). Continue administering the SlowFade until the whole coverslip is
close to full.
• Avoid adding too much SlowFade that it starts going under the broken coverslips – this will
cause the “bridge” to float, which makes sealing the edges (next step) difficult.
6.
Seal the edges of the coverslip with nail polish. Start by making brush strokes that are
perpendicular to the coverslip and bridges. Let dry. Repeat with brush strokes that are parallel to the
coverslip and bridges.
7. Store at 4°C in a dark slide holder
** mounted slides are good for several months at 4°C and several years (3+) at -20 or -80°C
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8.

Image using confocal microscope

Imaging:
*** try to image as quickly after mounting onto the slide as possible. Within the same week is usually
best***
1. Get training on the Confocal LSM700 prior to imaging brains alone
• This can be arranged through the microscopy core
2.
•

Key points for clean, publishable images:
Always use Nyquist sampling. This is easy on Zen software – make sure the “Optimize” button
on the Acquisition panel is pressed

•

Always ensure that the lens pinhole is 1 airy unit wide. This can be achieved by pressing the 1AU
button on the Channels panel. If the lens is changed, the 1AU button must be pressed again

•

Image with the highest number of Averaging possible (on the Acquisition panel). For single
slices, aim for 8 or 16. For Z-Stacks, aim for 4 or 8.

•

Beware of photo-bleaching! This occurs when a sample is exposed to the laser for a long period
of time. It results in the sample not be as excitable (i.e. bright fluorescence) as it was before.
• Z-Stacks 35 min and under are typically fine. Less averaging = quicker Z-stack. Wider
slice thickness = quicker Z-stack. If playing around with the settings for one brain, make
sure all brains within a sample are imaged using the same settings. You will need to
report these come publication time!

•

When optimizing a sample, choose the brain within the sample/slide that looks best (most
intact, all optic lobes attached, no obvious forcep marks). Optimize this brain using the Range
Indicator tool (little blue background, little red within tissue i.e. the background (blue) and
saturation (red) are controlled for). Image all brains within the sample (i.e. on that slide and
maybe other slides) using these microscope settings.

Image Analysis:
The Microscopy core can help with this! Computers with image analysis software are free to use and the
programs are always updated
Determining overall pixel intensity with ImageJ
i.e. how fluorescent an image is – this is a good analysis if trying to determine how much an RNAi
knocked down protein expression
1. Open image in Image J
2. Image Adjust Brightness/Contrast Set chose the range (specific to the BIT depth used while
imaging)
• This information is in the raw data file on Zen. But should always be 16 BIT
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3.
•

IF two channels (colors, flours) used while imaging, but you only want to analyze one channel…
Image color split channels

4.
Select image you want to analyze by clicking Analyze histogram (if Z-Stack hit analyze all)
record the mean and the standard deviation
5.

Repeat with remaining images!

Determining Manders co-localization with ImageJ
i.e. how much two proteins overlap – this is a good analysis if trying to determine how much of a protein
is in a cell type
1. Open image in Image J
2.
Image Adjust Brightness/Contrast Set chose the range (specific to the BIT depth used
while imaging)
• This information is in the raw data file on Zen. But should always be 16 BIT
3.

Split the two-color channels: Image color split channels

4.
Method one: analyze colocalization lots of options here! I would typically do coloc 2 and
Manders overlap coefficient reported, can interpret as a percent
5.
Method two: process image calculator multiple the images together the inverse of the
result shows colocalization
Notes:
How to make the solutions noted above:
0.3% (vol/vol) PBT solution:
Add 1.5 Triton-X 100 to 498.5mL 1 X PBS. Store at room temperature
4% (vol/vol) paraformaldehyde:
In a 0.5mL snap cap tube, add 100µL 20% w/v paraformaldehyde to 400µL PBT. Prepare fresh and place
on ice.
5% (vol/vol) normal goat serum (NGS): Add 50µL normal goat serum to 950µL PBT. Store this block
solution for short periods at 4°C (24-hour max)
Primary antibody: Dilute the primary antibody in freshly prepared 5% NGS. A 0.5mL tube requires 400µL
of diluted antibody. Diluted primary antibodies can be reused up to 3 times. Store in 4°C for up to 1
month-ish
Secondary antibody: Dilute the secondary antibody in freshly prepared 5% NGS. A 0.5mL tube required
400µL of diluted antibody. Prepare fresh and discard after use.
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____________________________________________________________________________
DO NOT do any staining steps (addition of primary antibody, secondary antibody, SlowFade) at a shorter
time at room temperature in Sanger Hall.
• The air in Sanger Hall has too much bacteria and the bacteria grow too fast at room temperature
and will take over the brains if the 4C steps are removed.
Bacteria growth under the confocal microscope transmittable light will look stringy and/or black. It will
compromise the exterior regions of the brain at first, but as time goes on the whole brain will be
compromised. Slides with brains with bacteria cannot be re-imaged weeks/months after the slide is
made.
____________________________________________________________________________
What does antibody penetration issues look like??
If the fluorescent signal is strong on the exterior portions of the brain, but not on the interior portions of
the brain. Each antibody is different, so if playing around with antibody concentrations does not fix this
(see below), choose a concentration that looked good on the exterior portions of the brain and increase
the amount of time the brains are exposed to this concentration at 4C
____________________________________________________________________________
So, you got a new primary or secondary antibody – how do you optimize concentrations so it is ready to
use??
Step One:
1. Check the literature – have any fly labs used this antibody for whole mounts before (adults or larva)
– what concentration did they use??
2. Dissect brains (w[A] or similar control stock) and stain with multiple concentrations chosen based on
previous literature (i.e. 1 concentration per tube of brains)
• Example: If previous literature used a 1:200 concentration, you can try…
• 1:100, 1:200, 1:500, 1:1000, 1:2000
• For this optimization, it is okay to only have 2-3 brains per concentration tube!
3.
Image and decide which concentration produces the best image in your hands. What other labs
have used may not be the best concentration for you!
Step Two:
4.
Dissect brains (w[A] or similar control stock)
5.
Stain with new reagent only!
• So, if a primary antibody, only stain with the primary antibody and not a secondary antibody. If a
secondary antibody, only stain with the secondary antibody and not a primary antibody.
6.
Image – Are you able to detect any fluorescent signal at reasonable power/gain settings?
• This will determine whether that reagent and the concentration you have chosen produced any
fluorescence on its own
• If no fluorescence is detectable – good! You are ready to use this concentration for experiments!
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•

If fluorescence is detectable – repeat with a lower concentration.
• If that doesn’t work… Talk to the microscopy core people about controlling for
background noise. It will be an extra step in your experimental image analysis, but the
data will still be trustworthy!

____________________________________________________________________________
Selecting antibodies for co-localization experiments:
1. Make sure the antibodies for the two different proteins you want to label are from different hosts
• Example: Mouse anti-X, Rabbit anti-Y
2.
Make sure the secondary antibodies are specific for their intended proteins primary antibody,
and are also from different hosts
• Example: Goat anti-mouse, Chicken anti-rabbit
What will not work:
• Primary: Mouse anti-X, Rabbit anti-Y
Secondary: Goat anti-mouse, Mouse anti-rabbit
**the Goat anti-mouse secondary will recognize the mouse anti-X primary antibody and the
mouse anti-rabbit secondary antibody**
3.
Make sure the fluorescent probes excitation/emission wavelengths do not overlap/minimally
overlap
• What works well:
• Alexa488 and Alexa568 (minimally overlapped)
• Alexa488 and Alexa647 (not overlapped)
•

Use this chart as a guide if purchasing new secondary antibodies for co-localization experiments:

•

UAS-GFP, UAS-RFP, UAS-YFP, etc. can be used as alternatives to antibodies. However, there
excitation/emission wavelengths should be treated the same as antibodies if doing colocalization
KML updated 5/2019-staining protocol adapted from Luo, 2006. A protocol for dissecting Drosophila
•

melanogaster brains for live imagine or immunostaining.
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4. Basic Polymerase Chain Reaction (PCR) Protocol

1. Dilute primers to 10 pmol/μl. The primers in the Primer Boxes in the -20°C freezer are at 1 nmol/μl
(1000 pmol/μl), so those need to be diluted 1:100 in dd H2O.
2. Thaw in hand and/or store on ice:
primers
Taq Buffer (in Taq box; includes MgCl2)
2.5 mM dNTPs
dd H2O
3. Each PCR sample or tube should contain:
1-5 µl template (e.g. 200 ng purified gDNA or 2-5 μl of squish prep)
5 µl forward primer
5 µl reverse primer
5 µl Taq Buffer
5 μl 2.5 mM dNTPs
0.3 µl Taq polymerase
X µl dd H2O to 50 μl total
Making each individual sample separately is cumbersome, so make a Master Mix for n+1 samples (i.e.
the number of samples you need to amplify plus 1). The master mix contains all components that will be
used in multiple samples. For example, if amplifying several different gDNAs with the same primer pairs,
the Master Mix should contain everything except the gDNAs. When making the Master mix, add all
components except for Taq polymerase, vortex to mix, add the Taq polymerase, then vortex to mix.
4. Aliquot the Master Mix into labeled 0.5 ml thin-walled PCR tubes and add remaining component(s).
5. Close lids and pulse vortex. If necessary, gently tap tubes to bring liquid to bottom.
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6. Place tubes in thermocycler, adjust thumb-wheel on lid until you start to feel a SMALL amount of
pressure, set program to appropriate program, enable heated lid, press Proceed. A run takes ~3 hours,
but can vary depending on cycling parameters.

5. DNA sequencing Protocol (GeneWiz)
1. PCR amplify the region to sequence
2. Run a gel on your PCR product using 3 µL with ladder (using 10 µL)
3. Add 2µL exosap to PCR product (~7µL) and run exosap cycle
4. Using the gel results, determine the relative concentration of your bands (2x brightness, 3x
brightness, etc.) and compare it to the ladder legend to determine concentration of your DNA (legend
should be on the ladder box or attached to the fume hood-note the µL the legend is for).
5. Using the included table for GeneWiz use Premixed purified PCR product samples, dilute your DNA
with ddH2O to the specified concentration
6. pipette 10µL of your diluted template per PCR tube (note: label tubes on the side with your initials
and the number of tube (IN1, IN2, IN3) and label the top with the number of the tube
7. add 5µL of your diluted primer (5µM) to each reaction tube (total volume is 15µL)
8. Enter your information into GeneWiz and print off the mailing sheet. To ship, seal the top of your
tubes with parafilm and seal in a bag. The mailing box is on floor 4 (MMRB)
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Example:
I run my gel using 10 µL of a 100bp New England BioLabs Ladder. I use 3µL of my PCR product in each
well. On the gel, my bands appear approximately 3.5x brighter than the brightest band on the ladder.
The brightest band on the ladder according to the legend is 95ng (in 10µL, as specified by the legend).
So, 95 ng x 3.5 is 332.5ng in my sample (which is 3µL). this means my concentration of DNA in 1 µL of my
sample is 110.8ng (332.5/3 gives us ng/1µL). I then run my remaining 7µL of PCR product with 2µL
exosap for the exosap cycle. When that (9µL) reaction is finished, I must dilute my sample to the desired
concentration (for 788 bop of purified PCR product, the end product must be 2ng/µL). Since I have 775.7
ng DNA in my 9µL sample (110.8 ng x 7µL PCR product +2µL exosap), I must add ddH2O to get a total
volume of 9uL product + exosap, I must add 378.8uL ddH2O to get a final concentration of 2 ng/µL. I
should then take 10µL of this final product and add 5uL of my diluted (1:20) sequencing primer, then
send my order in for sequencing.
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